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Abstract 
Adolescent athletes with type 1 diabetes (T1DM) face unique challenges when compared to 
peers with and without diabetes.  Continuous subcutaneous insulin infusion (CSII) provides a 
method of insulin delivery that can enhance flexibility in insulin regimens and lifestyle that may 
be especially appealing to the adolescent athlete.  No studies have explored the impact of 
athletics in this population.  This descriptive qualitative study explored and described the 
experiences of adolescent athletes using CSII as their primary insulin delivery method, with a 
focus on athletic participation and performance.   
 The purposeful sample consisted of four adolescent athletes, ages 13 to 15 years with 
T1DM, using CSII, in excellent diabetes control, and recently participated in organized sports 
activities.  After written informed consent, data were collected through a semi-structured 
interview with the adolescent and parent.  Results were transcribed verbatim and analyzed for 
emerging themes.  Four themes emerged from the transcripts along with multiple subcategories.  
The main themes included:  protecting the pump and infusion site; dealing with highs and lows; 
maximizing participation and performance; and keeping watch.  Information gathered from this 
study will prepare healthcare professionals to anticipate the needs of adolescent athletes using 
CSII when prescribing a diabetes management regimen.    
 
 
 
 
Chapter One: Introduction 
 Type 1 diabetes mellitus (T1DM) is an endocrine disorder characterized by absolute 
insulin deficiency secondary to pancreatic beta cell destruction from autoimmune or nonimmune 
factors, which results in abnormal macronutrient metabolism (Jones, Brashers, & Huether, 2010).  
In the United States alone, approximately 1 out of 400 children and adolescents has diabetes, and 
more than 15,000 children under 18 years of age are diagnosed with T1DM annually (American 
Diabetes Association [ADA], 2012a; Juvenile Diabetes Research Foundation [JDRF], 2011).  
The ADA (2008a) estimates that diabetes costs Americans $174 billion annually.  
The Diabetes Control and Complications Trial (DCCT) revolutionized diabetes care 
when it demonstrated that tight blood glucose control decreased the incidence of microvascular 
complications.  Another compelling finding was that, when compared to multiple dose 
injections, insulin pumps provided significant improvements in glycemic control and less 
hypoglycemia (ADA, 2012b).  Since these results were published, the use of intensified insulin 
therapy, in conjunction with nutrition, exercise, and self-monitoring of blood glucose has 
become the cornerstone of diabetes management.  As a result, CSII use in T1DM has 
significantly increased, especially in children and adolescents.  CSII is the most physiologic 
method of insulin delivery due to its capacity to nearly mimic normal patterns of insulin 
secretion over a 24-hour period (Kordonouri, Hartmann, & Danne, 2011).  CSII is often the 
modality of choice for children and adolescents and can be started at the time of diagnosis.  
When compared with multiple daily injections, CSII allows increased flexibility in eating and 
exercise schedules, fewer painful procedures, and the ability to more precisely tailor insulin 
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to the individual (Kordonouri et al., 2011; Bruttomesso, Costa, & Baritussio, 2009).    
 Adolescent athletes with diabetes can clearly stand to benefit from the enhanced 
flexibility of CSII.  While there have been numerous studies involving adolescent use of CSII, 
the focus has been on overall quality of life, self-management, and issues influencing metabolic 
control.  Adolescent athletes with T1DM face unique challenges when compared to their non-
athletic peers with T1DM.  Healthcare practitioners need to be aware of the challenges and 
concerns faced by these individuals in order to counsel them in managing this lifelong illness and 
maximizing their performance in sports.   
 Purpose and Research Question 
 The purpose of this descriptive qualitative study was to explore and describe the 
experiences of adolescent athletes with T1DM who use CSII as their primary insulin delivery 
method, in terms of athletic participation and performance.  Findings will be used to more 
accurately represent the issues and concerns related to CSII that face adolescent athletes.  This 
will subsequently prepare advanced practice nurses and other healthcare providers to address 
these factors when developing and implementing management strategies.   
 The following research question was addressed throughout the study:  In adolescent 
athletes with T1DM using CSII, what are the central concerns and factors regarding this 
treatment modality that affect individual athletic participation and performance? 
Theoretical Framework 
 The theoretical framework initially chosen for this study was the chronic illness trajectory 
framework developed by Corbin and Strauss (1991) and updated by Corbin (1998).  This 
framework is a middle range nursing theory derived from studies related to management of 
chronic illnesses and accounts of nurses’ actual practice experiences (McEwen, 2011).  Since 
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inception, the framework has guided research and directed the clinical management of chronic 
illnesses such as diabetes mellitus and chronic obstructive pulmonary disease.  The framework 
arose from the trajectory conceptual model, a grounded theory model developed by Strauss and 
associates over a period of 30 years, which demonstrated that chronic illnesses follow a course 
that shifts over time and can be influenced and managed by external factors (Corbin & Strauss, 
1991).   
The chronic illness model focuses on the role an individual plays in shaping the course of 
their illness within the context of their daily lives.  Additionally, the model provides a focus on 
quality of life.  The overarching concept of the model is the term trajectory, which signifies the 
course of an illness as well as the actions taken by those involved that guide that course (Corbin, 
1998; Corbin & Strauss, 1991).  In other words, the illness influences an individual’s life and 
that individual’s desires and expectations, in turn, influence how they manage the illness.  
According to Corbin and Strauss (1991), chronic illness has eight phases, starting with pre-
trajectory, the period before onset, and ending with dying.  Throughout a trajectory, an individual 
may experience periods of stability, instability, or crisis.  Trajectories are linear but variable and 
modifiable, and the patient can experience any of the interim phases throughout the course of the 
illness.  An individual’s trajectory within the context of an illness depends on a combination of 
actions by the individual, their family, and the healthcare team (Corbin, 1998).  Thus, the focus 
of care, specifically nursing care, must shift according to the individual’s current phase.   
The chronic illness model is appropriate to T1DM because individuals living with this 
illness can have both acute and long-term complications that can alter trajectory.  Preventing 
complications or crises requires an extensive knowledge base for both the individual and the 
healthcare team.  A nurse using the framework sees the illness as a larger picture rather than 
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simply the current symptoms or concerns.  The nurse can locate an individual’s position on the 
trajectory by gathering information from the individual, their family, and even other healthcare 
providers.  Then the nurse can evaluate the individual’s trajectory projection or vision of the 
illness course, as well as his/her own, to determine the conditions influencing management.  
Once this vision is clear, the nurse and individual can collaborate to set realistic goals and select 
the appropriate interventions.  During the implementation of these interventions, the nurse 
provides a combination of teaching, direct care, advocating, counseling, and referring (Corbin, 
1998).  One of the most crucial aspects of this process is follow-through, as once interventions 
are underway the nurse must continually reevaluate their effectiveness.  Furthermore, the model 
takes into consideration the complexity of the technology involved in managing illness and the 
fact that technology can cause side effects that can potentially impact the course of an illness.  
Indeed, technology is vital to effectively managing T1DM on a daily basis, and CSII is certainly 
the most complex technology utilized.   
The concepts of the chronic illness framework can be applied to this study in light of 
prior use in various chronic illnesses.  Consideration of the adolescent athlete’s perception of 
their illness and their goals and expectations is essential to understanding their experience in the 
context of T1DM.  Thus, this framework provides a broad lens through which the effect of CSII 
on athletic participation and performance can be viewed.   
Definition of Terms 
Adolescents with T1DM 
The term adolescent with T1DM refers to individuals between the ages of 13 and 18 
years diagnosed with type 1 diabetes mellitus.  T1DM encompasses International Statistical 
Classification of Diseases-9th Revision codes 250.1 to 250.9, and specifically 250.01 and 250.03  
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(World Health Organization, 1977).  
Athlete  
An athlete is an individual trained to compete in organized sports activities requiring 
specific physical skills.   
Participation 
Participation includes involvement in school, semi-professional, national or community 
organization athletics at least three days per week.     
Continuous Subcutaneous Insulin Infusion  
CSII is an insulin delivery method that uses an external electronic device to mimic 
normal pancreatic beta cell function through programmed basal and bolus doses (Bruttomesso et 
al., 2009).  CSII can describe devices that use an infusion set with tubing or the Omnipod 
system.  The term CSII may be used interchangeably with “insulin pump” or “pump.”                                                                                                                                                                         
Performance  
Performance is the manner or quality of an athlete’s function, specifically during training 
for or competition in organized sports activities.   
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Chapter Two: Review of Literature 
This chapter provides an overview of normal regulation of blood glucose and diabetes.  
The epidemiology, pathophysiology, complications, treatment with attention to management of 
athletes in particular, and prognosis of T1DM are discussed.  This is followed by a brief 
exploration of the implications for use of CSII in children and adolescents with a review of 
currently available devices.  Finally, a review of the available research with respect to the 
experience of living with T1DM in adolescence is presented.  
Diabetes Mellitus 
Normal Regulation of Blood Glucose 
Normal regulation of blood glucose occurs through the secretion of hormones produced 
by the alpha, beta, and delta cells in the islets of Langerhans within the pancreas.  Ideally, blood 
glucose control maintains levels between 70 mg/dl and 120 mg/dl.  Two pancreatic endocrine 
hormones are primarily responsible for maintaining normal blood glucose levels through 
management of carbohydrate metabolism: insulin and glucagon.  Alpha cells produce and secrete 
glucagon in response to hypoglycemia, which prompts gluconeogenesis and glycogenolysis in 
the liver, in turn raising blood glucose levels.  Alternately, when blood glucose is elevated, beta 
cells create and secrete insulin, which functions to lower blood glucose by stimulating cellular 
metabolism in the liver, muscle, and adipose tissue.  Insulin works to increase the uptake of 
glucose by cells and sends messages that suppress release of glucagon from the alpha cells.  A 
third hormone, somatostatin, is released by delta cells and is presumed to prevent glucagon and 
insulin release; however, its true role in metabolism is not yet known (Brashers & Jones, 2010).
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Diabetes Overview 
Diabetes mellitus is essentially a group of metabolic disorders characterized by impaired 
glucose tolerance and chronic hyperglycemia.  Glucose intolerance can arise from several 
disease processes and the ADA categorizes types of diabetes by cause (Jones et al., 2010).  
According to the ADA (2012a), there are four classifications for diabetes: T1DM, type 2 
diabetes, gestational diabetes, and other specific types.  T1DM is an absolute insulin deficiency 
and comprises approximately 5% to 10% of those with diabetes.  Type 2 diabetes ranges from 
insulin resistance with relative insulin deficiency to a defect in insulin secretion with insulin 
resistance and accounts for 90% to 95% of the total cases of diabetes (ADA, 2012a; Jones et al., 
2010).   
Gestational diabetes occurs in approximately 7% of all pregnancies and describes glucose 
intolerance that occurs, or is discovered initially, during pregnancy.  Most cases are due to 
pregnancy related glucose intolerance and resolve spontaneously after delivery.  However, in 
some cases, diagnosis of gestational diabetes is the result of previously undiagnosed diabetes 
(ADA, 2012a).  Based on the increased prevalence of type 2 diabetes in women of childbearing 
age, the ADA (2012a) has recommended diagnosing high-risk women with overt diabetes.   
Other specific types of diabetes include those caused by genetic abnormalities in beta cell 
or insulin function, pancreatic diseases (e.g., pancreatitis, trauma, infection, cancer), 
endocrinopathies (e.g., pheochromocytoma, Cushing’s syndrome), drugs and chemicals (e.g., 
nicotinic acid, pentamidine, glucocorticoids, toxins), and certain other uncommon autoimmune 
or genetic disorders (ADA, 2012a).  In their most recent position statement, the ADA has noted 
that some individuals cannot be clearly diagnosed with T1DM or type 2 diabetes based on 
varying presentations and progression in both types.  This situation can be true of children, 
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adolescents, and adults, but over time the true diagnosis usually becomes clear (ADA, 2012b).  
This study will focus on young individuals with T1DM.  
Type 1 Diabetes Mellitus 
Epidemiology  
As previously mentioned, T1DM comprises approximately 5% to 10% of all cases of 
diabetes, affecting as many as three million Americans (JDRF, 2011; Jones et al., 2010).  The 
current prevalence rate is 0.17% with no documented increase in the United States.  As it is one 
of the most common childhood illnesses, T1DM was once referred to as juvenile diabetes.  This 
term is no longer in use because onset, although rare in adults over age 30, can occur at any age.  
Onset peaks at age 11 to 13 years (Jones et al., 2010).  T1DM occurs equally in males and 
females, with onset usually slightly earlier in females, and typically presents in normal or 
underweight individuals.  T1DM is approximately 1.5 to 2 times more common in whites than in 
nonwhites, and there are significantly higher rates for those of Scandinavian descent than those 
of central or southern European descent.  An increase in the number of cases diagnosed in the 
autumn and winter months demonstrates a seasonal pattern.  Additionally, T1DM appears to 
have a genetic component as 10% to 13% of those newly diagnosed have at least one first-degree 
 relative with T1DM (Jones et al., 2010).    
Pathophysiology 
  T1DM is the result of the loss of pancreatic beta cells, either from autoimmune or 
idiopathic causes, which causes a complete lack of insulin (ADA, 2012a; Jones et al., 2010).  
Approximately 90% of T1DM is immune-mediated, in which an individual’s immune system 
fails to recognize its own beta cells and launches a cell-mediated immune response resulting in 
complete destruction of the cells (Jones et al., 2010).  The rate of beta cell destruction varies, 
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with some developing severe symptoms quickly and others retaining beta cell function for many 
years.    
In 85% to 90% of those diagnosed with T1DM, testing reveals one or more genetic 
markers for beta cell destruction, such as islet cell antibodies, autoantibodies to insulin, 
autoantibodies to GAD (glutamic acid decarboxylase), or antibodies to tyrosine phosphatase IA-
2 and IA-2β (ADA, 2012a).  The true nature of genetic predisposition is still unknown, but there 
is a strong association with markers on human leukocyte antigen (HLA), with risk of developing 
T1DM increasing five to eight times when present.  An individual heterogeneous for HLA-DR3 
or DR4 has approximately 20 to 40 times the risk of developing T1DM compared to the general 
population and may have predispositions for other immune disorders, such as Grave’s disease, 
Hashimoto’s thyroiditis, celiac disease, and Addison’s disease (ADA, 2012a; Jones et al., 2010).   
Environmental factors, such as chemicals, viruses (mumps, coxsackievirus, rubella, and 
cytomegalovirus), cow’s milk, and stress are also thought to contribute to development of 
T1DM.  However, these potential triggers are still poorly defined (Jones  
et al., 2010).   
Approximately 10% of T1DM is idiopathic or nonimmune mediated with no defined 
cause of beta cell destruction.  Idiopathic T1DM is genetically-linked and typically occurs in 
individuals of Asian or African descent.  These individuals have varying levels of insulin 
deficiency and need for insulin replacement may be episodic (ADA, 2012a; Jones et al., 2010).   
T1DM onset occurs when 80% to 90% of pancreatic beta cells can no longer function 
normally.  The decreased availability or absolute absence of insulin, in conjunction with the 
relative excess of glucagon resulting from loss of insulin paracrine function, leads to increased 
blood glucose and increased fat catabolism with more fatty acids delivered to the liver.  The 
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resulting increased gluconeogenesis, glycogenolysis, and lipolysis further contribute to 
hyperglycemia and produce circulating ketone bodies.  Ketone accumulation causes a decrease in 
pH that leads to metabolic acidosis.  Excess blood glucose and ketone bodies eventually 
overwhelm the renal system, leading to excretion via osmotic diuresis (Jones et al., 2010).   
T1DM diagnosis usually occurs when an individual presents with the classic symptoms 
of increased thirst (polydipsia), increased hunger (polyphagia), increased urination (polyuria), 
weight loss, and fatigue with concomitant fasting and postprandial hyperglycemia.  Polydipsia 
occurs as a result of hypothalamic stimulation related to intracellular dehydration that occurs as 
increased glucose causes water to be osmotically pulled from cells.  Since the body cannot use 
circulating glucose for energy, polyphagia occurs as the body tries to replace depleted cellular 
stores of carbohydrates, fats, and protein.  Polyuria results from osmotic diuresis and often 
presents as nocturia.  As the blood glucose level exceeds the renal threshold, glucose spills into 
the urine (glycosuria), accompanied by large amounts of water.  Weight loss occurs because of a 
combination of fluid loss and depletion of fats and proteins.  Fatigue results from metabolic 
changes and sleep deprivation from nocturia (Jones et al., 2010). 
  For diagnostic purposes, hyperglycemia is a fasting plasma glucose (FPG) ≥ 126 mg/dl 
or a two hour postprandial plasma glucose ≥ 200 mg/dl.  If an individual presents with signs or 
symptoms of hyperglycemia, random plasma glucose ≥ 200 mg/dl meets diagnostic criteria.  
Additionally, blood glucose measurement over time with glycosylated hemoglobin (HgbA1C) ≥ 
6.5% can assist in diagnosis (ADA, 2012b).   
If the classic symptoms of hyperglycemia are not recognized and treated, a type of 
metabolic acidosis called diabetic ketoacidosis (DKA) can occur.  For many children, diagnosis 
of T1DM occurs when they present with signs and symptoms of DKA (ADA, 2012b; Jones et 
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al., 2010).  DKA ensues when there is a dangerous drop in serum pH secondary to circulating 
ketone bodies.  In the presence of insulin deficiency, increased lipolysis occurs and results in the 
creation of large amounts of fatty acids.  As the liver uses these fatty acids, it produces 
acetoacetic and β-hydroxybutyric acids that increase ketone concentrations.  Normally the body 
can use ketones as an energy source, but accumulation exceeding the body’s threshold results in 
a progressive rise of ketone levels in the blood (hyperketonemia).  Initially, the body’s buffering 
systems can limit ketonemia, removing excess ketones through urination (ketonuria).  If not 
treated, urinary compensation fails and further accumulation of ketones leads to decreased serum 
pH, resulting in metabolic acidosis.  Respiratory compensation results in a rapid, shallow 
breathing pattern known as Kussmaul respirations, allowing excess acetone to be blown off and 
producing the characteristic fruity breath of DKA.  If treatment with fluids, low-dose insulin, and 
electrolyte replacement does not happen immediately, coma, and possibly death, can occur 
(Jones et al., 2010; Kitabchi et al., 2001).   
Complications  
 T1DM, like most chronic illnesses, can result in both acute and chronic complications if 
not managed effectively.  Acute complications include hypoglycemia, hyperglycemia and DKA, 
the Somogyi effect, and the dawn phenomenon.  Chronic complications include microvascular 
and macrovascular diseases.  In addition, individuals with poorly controlled diabetes are at 
increased risk for infection.  
 Hypoglycemia.  Hypoglycemia, often called insulin shock or insulin reaction, is a 
lowered blood glucose level that can occur due to a number of factors.  Hypoglycemia occurs in 
at least 90% of individuals with T1DM and is the most limiting factor in management (ADA, 
2012b; Jones et al., 2010).  Essentially, hypoglycemia is blood glucose ≤ 70 mg/dl that results 
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from excessive insulin relative to available carbohydrates   (ADA, 2012b).  Most commonly, this 
condition develops as a result of intentional or accidental overdose of insulin.  This can be in 
conjunction with insufficient food intake, increased exercise, decreased insulin needs, ingestion 
of alcohol, or certain medications.   
Symptoms of hypoglycemia often vary from person to person, but are usually consistent 
within an individual, and include either adrenergic or neuroglycopenic symptoms.  Adrenergic 
symptoms occur with activation of the sympathetic nervous system due to a rapid decrease in 
blood glucose and consist of tachycardia, palpitations, diaphoresis, pallor, tremors, and anxiety.  
Neuroglycopenic symptoms result from a drop in glucose supply to the brain and include 
headache, dizziness, irritability, fatigue, hunger, confusion, seizures, and possibly coma (Jones et 
al., 2010).   
If symptoms are mild, the ADA (2012b) recommends treatment with 15 to 20 grams of 
glucose; however, any form of carbohydrate containing glucose is acceptable.  Blood glucose 
should be checked after 15 minutes and treatment repeated if hypoglycemia persists.  Once blood 
glucose has returned to normal, the individual should eat a meal or snack to prevent recurrence.  
If symptoms are severe or the individual loses consciousness and cannot take oral glucose, 
treatment is subcutaneous injection of glucagon (ADA, 2012b).  Individuals with T1DM and 
their caregivers should understand the contributing factors for hypoglycemia, be aware of the 
signs and symptoms, and know how to treat symptoms when they occur.   
 Hyperglycemia and DKA.  Hyperglycemia, in contrast to hypoglycemia, occurs when 
there is a surplus of carbohydrates (glucose) in the blood relative to insulin.  This condition 
characterizes diabetes, and poor glycemic management is usually the culprit.  In individuals with 
diabetes, hyperglycemia is blood glucose ≥180 mg/dl (ADA, 2012b).  Failure to take insulin, 
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insufficient insulin relative to carbohydrate intake, increased stress, illness, surgery, or 
uncontrolled dietary habits can all lead to a hyperglycemic state.  In instances of illness or stress 
where there is insulin deficiency, “there is an increase in insulin counterregulatory hormones 
including catecholamines, cortisol, glucagon, and GH [growth hormone]” (Jones et al., 2010, p. 
756).  These hormones increase glucose production and decrease use of glucose.  The lack of 
circulating insulin prevents glucose uptake by cells, thus increasing blood glucose levels (Jones 
et al., 2010).   
The signs and symptoms of hyperglycemia include polyuria, polydipsia, polyphagia, 
headache, weight loss, nausea and vomiting, lethargy, and general malaise.  As mentioned in the 
discussion on pathophysiology, unless these symptoms are recognized and managed quickly, 
DKA can follow (Jones et al., 2010).  
Somogyi effect.  The Somogyi effect, common in children with T1DM, is “a 
combination of hypoglycemia followed by rebound hyperglycemia” (Jones et al., 2010, p. 758).  
Hypoglycemia stimulates hormones such as epinephrine, growth hormone, cortisol, and 
glucagon that act to increase blood glucose via gluconeogenesis and simultaneously inhibit 
glucose use.  The result is hyperglycemia that can last up to 48 hours.  Usually, excessive 
carbohydrate consumption is to blame and leads to fluctuating blood glucose levels.  Nocturnal 
hypoglycemia can cause nightmares and morning headaches.  Diagnosis entails measuring blood 
glucose during the night, preferably with continuous glucose monitoring, and management 
involves changes in insulin administration (Jones et al., 2010).   
 Dawn phenomenon.  The dawn phenomenon is early morning hyperglycemia with no 
nocturnal hypoglycemia.  This condition is thought to be related to increases of growth hormone, 
but can also occur when attempting to treat the Somogyi effect.  Like the Somogyi effect,  
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changes in insulin dose and timing usually treat the dawn phenomenon (Jones et al., 2010).   
 Microvascular disease.  The microvascular complications that can occur with diabetes 
are the leading cause of serious conditions such as neuropathies, blindness, and renal failure.  
Cells in the nerves, eye lens, kidneys, red blood cells, and blood vessels do not require insulin for 
glucose uptake.  Instead, they utilize an alternative pathway to metabolize glucose, known as the 
polyol pathway.  In the presence of hyperglycemia, cell injury occurs over time as glucose shifts 
to this pathway.  Glucose converts to sorbitol and then fructose, the accumulation of which leads 
to cell damage from osmotic pressure.  Additionally, with persistent hyperglycemia, glucose 
binds permanently to collagen and other proteins, forming advanced glycosylated end products 
(AGEs).  The accumulation of AGEs in red blood cells, blood vessel walls, and interstitial tissues 
lead to damage to the retina that can lead to blindness (retinopathy), damage to the nephrons of 
the kidneys (nephropathy), and damage to peripheral nerves (neuropathy) causing pain and 
paresthesia (Jones et al., 2010).  Prevention of these complications, as demonstrated in the 
DCCT, hinges on tight glycemic control (ADA, 2012b).  
 Macrovascular disease.  Like microvascular diseases, macrovascular diseases result 
from damage from persistent hyperglycemia and AGEs.  These changes can lead to accelerated 
development of atherosclerosis, resulting in increased risk for coronary artery disease, 
myocardial infarction, stroke, and peripheral vascular disease.  As with other complications, tight 
glycemic control is the key factor in reducing these risks (Jones et al., 2010).   
 Infection.  Individuals with diabetes are at increased risk for infection for several 
reasons.  Declines in sensory perception due to retinopathy or peripheral neuropathy can lead to 
diminished ability to prevent or recognize breaks in skin integrity, which can eventually result in 
open wounds or soft tissue infection.  Once skin integrity is compromised, tissues are more 
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vulnerable to pathogens due to hypoxia from vascular changes.  Pathogens that have invaded 
tissues may replicate quickly due to the increased glucose in body fluids.  Additionally, there is a 
decreased supply of white blood cells available to attack pathogens and facilitate healing 
secondary to impaired blood flow from vascular changes.  Furthermore, white blood cell 
function, chemotaxis, and phagocytosis can be weakened by ischemia and hyperglycemia.  
Finally, inflammatory responses to infectious incursion as well as signs of infection may be 
decreased (Jones et al., 2010).   
Treatment for T1DM 
Since T1DM is a chronic illness with no present cure, treatment is more appropriately 
termed management.  The focus of T1DM management is tight glycemic control to maintain 
close to normal blood glucose levels and prevent complications (ADA, 2012b).  Regimens 
should be tailored to age, activity level, and sociocultural factors.  T1DM management should 
begin with a comprehensive assessment of complications and comorbidities, with the aim of 
developing an appropriate regimen of insulin therapy, medical nutritional therapy, physical 
activity, and self-monitoring of blood glucose (ADA, 2012b; Jones et al., 2010).  According to 
ADA (2012b) guidelines, medical care should consist of a collaborative team approach, headed 
by a physician, and including nurse practitioners, physician assistants, nurses, dietitians, 
pharmacists, and mental health professionals with expertise in diabetes.  Based on the population 
chosen for this study, discussion of T1DM management will focus specifically on the needs of 
children, adolescents, and athletes.   
Insulin Therapy   
Based on the body’s inability to produce sufficient insulin, the chief pharmacologic 
treatment of T1DM is daily replacement with insulin and insulin analogs (ADA, 2012b; Jones et  
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al., 2010).  Per ADA (2012b) recommendations, insulin therapy should include the following: 
multiple dose injections (MDIs) or CSII therapy; matching pre-meal insulin dose to carbohydrate 
intake, blood glucose, and planned activity level; and use of insulin analogs to prevent 
hypoglycemia.  Currently, combinations of rapid-, short-, intermediate-, and long-acting insulin 
and analogs constitute insulin treatment (Kapustin, 2009).  See Table 2.1 for the characteristics 
and duration of insulin types used.  
Table 2.1  
 
Insulin Action, Onset, Peak, and Duration 
Insulin and Action Onset Peak Duration 
Rapid-acting 
     lispro (Humalog) 
     aspart (Novolog) 
     glulisine (Apidra) 
Short-acting  
     Regular (R) 
Intermediate-acting 
     NPH (N) 
Long-acting 
     glargnine (Lantus) 
     detemir (Levemir) 
 
5-15 min 
5-15 min  
5-15 min 
 
30-60 min  
 
2-4 hours 
 
2 hours 
1 hour 
 
30-90 min 
1-3 hours 
30-90 min  
 
2-4 hours 
 
6-10 hours 
 
No peak 
No peak 
 
3-4 hours 
3-5 hours 
3-4 hours 
 
6-8 hours 
 
10-16 hours 
 
20-24 hours 
6-24 hours 
Note.  Adapted from Pharmacology for the Primary Care Provider (p. 576), by M. W. Edmunds 
& M.S. Mayhew, 2009, Maryland Heights, MO: Mosby Elsevier.  
 In general, long-acting analogs and intermediate-acting insulin maintain a constant basal 
level of insulin, while rapid-acting analogs and short-acting (regular) insulin provide bolus 
coverage for meals and snacks.  If an individual misses a meal, the rapid-acting dose should not 
be taken (Kapustin, 2009).  There are general guidelines regarding insulin dosing and 
scheduling; for example, one unit of regular insulin provides coverage for 10 to 15 grams of 
carbohydrate.  However, maximizing glycemic control requires individualization.  In children 
and adolescents, dosing is guided by body weight, pubertal status, and age.  Children with a new 
diagnosis of T1DM may require lower total daily doses of 0.5 to 1 units/kg, while they may need 
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doses of as much as 1.5 units/kg during puberty due to rapid growth and hormonal influences 
(Silverstein et al., 2005).  Additional insulin may be necessary based on blood glucose level, 
carbohydrate intake, or individual response (Kapustin, 2009).   
 Choosing the appropriate insulin regimen for children or adolescents involves 
consideration of their daily activities and eating habits.  A common approach that provides firm 
glycemic control is the basal/bolus regimen, which combines a daily dose of a long-acting analog 
with several doses of a rapid-acting analog taken before meals or snacks.  The basal dose is 
typically administered at bedtime, and pre-meal bolus doses are based on the individual’s current 
blood glucose, planned carbohydrate intake in grams, and anticipated physical activity.  
However, as many children and adolescents tend to eat several snacks or small meals throughout 
the day rather than three large meals, optimal coverage using this regimen could require six to 
seven injections per day.  A regimen that uses two to three doses of rapid-acting or regular 
insulin in conjunction with intermediate-acting insulin is sometimes preferable, as this allows 
flexibility in eating times (Silverstein et al., 2005).   
 According to Silverstein et al. (2005), the ADA recommendation is the use of basal/bolus 
regimens, citing that the combination of rapid-acting and intermediate-acting insulin is not 
sufficient to maintain target glycemic control in over half of the pediatric population.  Although 
MDIs allow flexibility in achieving glycemic control, the number of injections combined with 
the need to rotate injection sites can present a problem with adherence.  CSII, or insulin pumps, 
essentially eliminate the need for multiple injections and simplify insulin administration by 
providing a continuous subcutaneous infusion of insulin with programmable basal and bolus 
doses (Silverstein et al., 2005).   
 Insulin administration for athletes, in particular, can present unique challenges.  During  
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exercise, there is a significant increase in glucose uptake by muscles, and hormones such as 
glucagon, cortisol, and catecholamines work to restore blood glucose.  Once these hormones are 
exhausted it is difficult to prevent post-exercise hypoglycemia; therefore, athletes must closely 
monitor blood glucose for up to 24 hours after exercise.  Another issue is hyperglycemia 
resulting from relative low insulin levels.  In the absence of insulin, glucose uptake by muscles is 
hindered, causing reliance on alternative energy sources, such as fats.  The combination of 
gluconeogenesis and decreased glucose uptake can lead to severe hyperglycemia that is 
detrimental to performance and can persist until the individual receives insulin (Shugart, 
Jackson, & Fields, 2010).   
Guidelines set forth by Shugart et al. (2010) presented adjustments for insulin doses in 
moderate-intensity and high-intensity exercise.  Athletes involved in moderate-intensity exercise 
who use long-acting basal insulin should not make any adjustments, but should closely monitor 
blood glucose.  However, those using short-acting insulin should decrease preexercise doses by 
20% to 50%.  When engaging in high-intensity exercise, guidelines are more complicated.  For 
example, athletes who use a basal/bolus regimen planning mid-morning exercise should decrease 
their breakfast bolus dose, but make no change to their basal dose.  The decreased dose is based 
on projecting the maximal oxygen uptake (VO2 max): If the estimated VO2 max is 65% the dose 
should be decreased by the same percentage.  However, athletes who use intermediate-acting and 
short-acting insulin should, based on projected VO2 max, decrease both the breakfast 
intermediate-acting dose and any short-acting doses that would be taken before exercise.  
Alternately, athletes can choose to increase preexercise carbohydrate intake.  In either case, 
blood glucose should be tested during training to determine individual responses (Shugart et al., 
2010).   
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Medical Nutrition Therapy   
Optimal management of T1DM includes a medical nutrition therapy (MNT) regimen, 
preferably designed by a registered dietitian (ADA, 2012b).  The ADA (2008b) reported that 
clinical trials of MNT have demonstrated HgbA1C decreases of up to 1% in T1DM, with 
improvements noted within three to six months of initiation.  The goal of MNT is to provide 
adequate nutrition to support growth and development and meet individual blood glucose, lipid, 
and blood pressure goals while preventing hypoglycemia.  Nutrient recommendations for 
children and adolescents with T1DM are the same as those established for healthy children, and 
growth should be evaluated on a regular basis by following height, weight, and BMI patterns 
according to the Centers for Disease Control and Prevention (CDC) pediatric growth charts.  
Calories should be restricted if a child becomes overweight (Silverstein et al., 2005).   
The Dose Adjustment for Normal Eating study revealed that carbohydrate counting for 
meals and snacks and using a carbohydrate to insulin ratio to adjust insulin doses results in a 
decrease in HgbA1C and improved patient satisfaction and quality of life (ADA, 2008b; 
Silverstein et al., 2005).  Although there is evidence that calculating carbohydrate content is the 
most crucial aspect in calculating premeal insulin doses, other methods may also be used to 
calculate carbohydrate intake, including the exchange system and experience-based estimation 
(ADA, 2008b).  The key to successful medical nutrition therapy is careful meal planning with 
consideration of several factors: food preferences, physical activity, family eating patterns and 
schedules, cultural aspects, and appetite.  Additionally, families must receive adequate education 
to understand the impact of food choices on blood glucose, with emphasis on avoiding low-
carbohydrate diets (Silverstein et al., 2005).   
Nutrition management for athletes focuses on providing a diet that can maximize  
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performance and minimize fatigue, while preventing hyperglycemia and hypoglycemia.  There  
are no specific daily recommendations for athletes with T1DM, but guidelines focus primarily on 
carbohydrate intake.  Overall, carbohydrate intake should remain near 7 g/kg/day, and athletes 
with T1DM should avoid common practices such as carbohydrate loading prior to an event.  An 
athlete’s specific needs should be considered, and finding the optimal regimen may require a trial 
and error approach (Gallen, Hume, & Lumb, 2011; Shugart et al., 2010).   
Physical Activity   
An essential aspect of T1DM management is physical activity.  Regular exercise provides 
a variety of benefits to physical and mental health, such as weight and lipid management, 
cardiorespiratory and muscular fitness, and an overall improved sense of well-being (Silverstein 
et al., 2005).  Physiologically, exercise increases glucose uptake by muscle cells and improves 
insulin sensitivity (D’hooge et al., 2011; Shugart et al., 2010).  Studies examining the impact of 
aerobic and resistance training on metabolic control and quality of life in adolescents with T1DM 
have demonstrated significant decreases in daily insulin requirements, as well as increases in 
physical fitness and perceived quality of life (D’hooge et al., 2011; Faulkner, 2010).  However, 
studies have failed to show any significant improvement in long-term glycemic control or 
metabolic control (D’Hooge et al., 2011; Faulkner, 2010; Silverstein et al., 2005).   
Despite the lack of data regarding the metabolic benefits of exercise in T1DM  
management, the ADA has stated that children and adolescents with T1DM should  
observe the CDC and American Academy of Sports Medicine guidelines of 30 to 60 minutes of 
moderate physical activity daily.  As previously discussed, the increased uptake of glucose by 
muscle cells can lead to hypoglycemia with increased exercise intensity, duration, or frequency 
and accounts for 10% to 20% of hypoglycemic episodes in children and adolescents.  Thus, the 
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ADA recommends blood glucose monitoring prior to the start of exercise (Silverstein et al., 
2005).  If blood glucose is below the target level of 100 mg/dl, 15 grams of carbohydrate should 
be ingested prior to the start of any exercise (ADA, 2012b; Silverstein et al., 2005).  An 
additional 15 grams of carbohydrate may be needed prior to intense exercise, especially if 
exceeding 30 minutes.  In the case of sustained, intense exercise, such as competitive sports, 
blood glucose should be checked hourly and again following completion of exercise.  Easily 
absorbed sources of glucose, such as sports beverages with electrolytes, may be needed to 
maintain adequate blood glucose (Shugart et al., 2010; Silverstein et al., 2005).  To better guide 
insulin adjustments, athletes involved in seasonal sports activities should also monitor blood 
glucose during the 12-hour period following exercise (Silverstein et al., 2005).  Moderate or 
intense exercise is contraindicated in DKA and in cases of hyperglycemia with ketosis as 
evidenced by the presence of ketones in blood or urine (ADA, 2012b).   
Self-Monitoring Blood Glucose   
As diabetes is a lifelong condition, the overall goal of treatment is self-management.  The 
multidisciplinary team should focus on providing individuals with the tools and education to 
manage their condition and avoid complications.  Since all insulin regimens are contingent upon 
blood glucose measurement, one of the most important aspects of self-management is self-
monitoring blood glucose (SMBG) to determine insulin dosing or other interventions (Silverstein 
et al., 2005).  According to the ADA, there is a strong association between SMBG and glycemic 
control (ADA, 2012b; Silverstein et al., 2005).  Children and adolescents with T1DM usually 
need to check blood glucose at least three to four times per day to ensure satisfactory glycemic 
control.  Preprandial checks determine bolus doses while postprandial and overnight levels 
determine insulin response and necessary adjustments.  Young children may not be able to 
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recognize or report signs or symptoms of hypoglycemia, so safe management may require 
additional testing, especially with the characteristic erratic eating patterns of childhood 
(Silverstein et al., 2005).   
Blood glucose monitoring should be performed with federally approved devices and 
calibrated on a regular basis.  Although most devices feature an internal memory or removable 
chip, individuals should also maintain daily logs that can aid in collaborating with healthcare 
providers to detect areas of concern or doses that need adjustment (ADA, 2012b; Silverstein et 
al., 2005).  Blood glucose goals for children and adolescents vary by age group, and while there 
are recommended targets, goals should always be based on individual needs.  For children less 
than six years of age preprandial blood glucose should be 100 mg/dl to180 mg/dl and bedtime or 
overnight glucose should be 110mg/dl to 200 mg/dl.  School-age children (ages 6-12) should aim 
for a preprandial level of 90 mg/dl to 180 mg/dl and a bedtime or overnight level of 100 mg/dl 
to180 mg/dl.  Goals for adolescents (ages 13-19) are similar to those for adults, with a 
preprandial goal of 90 mg/dl to130 mg/dl and a bedtime goal of 90 mg/dl to150 mg/dl 
(Silverstein et al., 2005).   
In addition to SMBG, it is necessary for longer-term blood glucose levels to be 
monitored, at regular intervals, to ensure effective glycemic control and identify issues that could 
promote the development of complications.  Glycosylated hemoglobin measures the average 
glucose to which red blood cells have been exposed over their 120-day life cycle.  This value can 
be used to assess therapy effectiveness as well as identify chronic hyperglycemia that may not be 
reflected in daily levels (Jones et al., 2010).  In general, the goal for HgbA1C in adults is 7%. 
However, this can be increased up to as much as 8.5% in younger children, based on their risk 
for undetected hypoglycemia (Silverstein et al., 2005).  
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Self-Management 
  The ultimate goal of T1DM management is self-management.  During childhood, 
although the child may participate in care, parents (or primary caregivers) are largely responsible 
for managing T1DM on a daily basis.  It is during adolescence that responsibility begins to shift 
to the child (Olinder, Nhylin, & Smide, 2010).  According to the ADA, while adolescents are 
developmentally mature enough to handle the technical aspects of diabetes management, they 
continue to require assistance with decision-making (Silverstein et al., 2005).  In addition, 
studies have demonstrated a link between glycemic control and parental involvement in care.  
Based on this, the ADA recommends shared management, with parents remaining involved to 
the extent that is suitable for parent and child (Silverstein et al., 2005).   
Prognosis 
 T1DM prognosis depends primarily on the presence of short-term and long-term 
complications.  Most deaths of individuals with T1DM occur with delays in diagnosis or 
treatment of DKA or severe hypoglycemia; young children and adolescents are at greatest risk.  
While advances in management have significantly lowered mortality in children diagnosed with 
T1DM, life expectancy remains lowered by an average of 13 to 19 years when compared to those 
who do not have diabetes.  Long-term complications typically occur later in life, but prevention 
requires effective lifelong glycemic control as well as managing comorbidities related to lipids, 
blood pressure, and weight (Lamb, 2011; Romesh, 2012).  
Continuous Subcutaneous Insulin Infusion 
CSII Overview 
 Continuous subcutaneous insulin infusion systems, more commonly called insulin 
pumps, eliminate the need for multiple daily injections by continuously delivering rapid-acting 
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or short-acting insulin via a subcutaneous catheter inserted in the arm, abdomen, thigh, or upper 
gluteal region.  Most CSII systems consist of a battery-operated electronic pump, an internal 
reservoir, and an infusion set with tubing and a cannula for subcutaneous catheter insertion.  A 
newer device, the OmniPod®, features a personal diabetes manager (PDM), similar to a personal 
digital assistant.  The OmniPod does not require tubing, but instead uses a small single-use pod 
that stays in place for 72 hours.  Once the catheter or pod is in place, the user can program basal 
rates, boluses to cover carbohydrates, and correction or supplemental doses.  CSII allows greater 
flexibility in meal times and amounts, and allows the user to adapt their insulin regimen to their 
individual lifestyle.  Most pumps are water-resistant or waterproof, but can be easily 
disconnected while bathing, showering, or swimming; the pod is waterproof up to eight feet.  For 
athletes, the pump can be worn during activity with an armband or elastic waistband and case.  
Use is often discouraged during contact sports because of risk of  
damage or injury, but the pump can be safely removed for one to two hours (ADA, n.d.).   
 Studies on CSII have presented evidence of lowered HgbA1C when compared to MDI 
and clearly demonstrate that CSII can increase glycemic control without increasing the risk of 
hypoglycemia (Kourdonouri et al., 2011).  In addition to increased flexibility, advantages to 
using CSII over MDI include decreased needle anxiety, improved accuracy, decreased 
occurrence of dawn phenomenon, and decreased risk of severe hypoglycemia.  There are also a 
few drawbacks such as the possibility of pump failure, accidental disconnection or 
decannulation, missed boluses, risk of site infection, and complacency with blood glucose 
testing.  Additionally, individuals must be willing to perform blood glucose testing at least four 
times per day and must be comfortable wearing the pump 24 hours a day.  Most of these issues 
can be resolved with solid teaching at initiation and throughout therapy (ADA, n.d.; Low, 
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Massaa, Lehman, & Olshan, 2005).  One major disadvantage can be the substantial cost of the 
pump and supplies.  Most insurance companies will cover the majority of the startup price and 
monthly supplies, but those without insurance may spend approximately $6000 at initiation of 
therapy and up to $200 per month for supplies (ADA, n.d.; Soraya, Watts, & Leichter, 2002).   
Implications for Children and Adolescents 
In the 30 years since CSII was first introduced, a multitude of studies, including 
randomized clinical trials, have demonstrated safety and efficacy in children and adolescents.  
Pediatric endocrinology clinics regularly prescribe CSII for pediatric patients, regardless of age, 
and therapy can begin at onset of T1DM.  Though any child with T1DM can use CSII, it is 
specifically indicated for those with frequent episodes of severe hypoglycemia, problematic 
fluctuations of blood glucose levels or HgbA1C, poor metabolic control, signs or symptoms of 
microvascular complications, or a particularly rigorous insulin schedule that impacts lifestyle.  
Additionally, CSII is the recommended insulin delivery method for competitive athletes, children 
with a severe fear of needles, and young children with erratic eating habits (Bruttomesso et al., 
2009; Shalitin & Phillip, 2008).  CSII is contraindicated in cases of non-compliance, refusal to 
wear the device, reluctance or failure to perform at least four blood glucose checks per day, and 
certain psychiatric conditions, especially suicide attempts or eating disorders (Bruttomesso et al., 
2009).  Initiation of CSII ideally begins with an agreement between the caregivers, child (if old 
enough to have input), and multidisciplinary team after consideration of indications and 
individual needs.  A comprehensive assessment evaluating the ability of caregivers to supervise 
or manage pump use and blood glucose testing is especially important with young children.  
Success of CSII therapy is incumbent upon intensive pump training at the initiation of therapy 
and continued frequent contact.  Thorough teaching of pump function, management of alarms 
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and expected issues, infusion set insertion, and potential complications is essential.  Additionally, 
families should be educated on backup procedures, such as giving injections with syringes or 
pens, in case of pump failure or other treatment difficulties.  This is particularly significant for 
those initiating CSII at the onset of T1DM (Shalitin & Phillip, 2008).   
 Based on development, children and adolescents require some modifications to the 
typical CSII setup.  Insulin needs vary throughout childhood and adolescence.  Young children 
tend to need higher basal rates in the afternoon, whereas adolescents tend to need increases at 
dawn and dusk.  This presents a unique issue for practitioners as there are no standardized or 
consensus basal dose rates for pediatric populations.  Fasting tests can be performed to assess 
basal rate needs independent of carbohydrate intake (Kordonouri et al., 2011).  Another issue 
specific to children and adolescents is the choice of insulin and infusion sets.  In their review, 
Kordonouri et al. (2011) cited the results of the German PedPump study in which 91% of 
subjects used a short-acting analog.  The study indicated that the three rapid-acting analogs 
approved for use with CSII provided more timely adjustment to rapid glucose fluctuations 
common in children.  However, rapid-acting analogs are available only as 100 units per ml.  In 
very young children requiring a low basal rate, this concentration is impractical as it may result 
in catheter obstruction and may necessitate the use of a non-insulin diluent.  Needle length and 
composition are also of concern given the lower amount of subcutaneous fat in children.  Shorter 
needles (6-8 mm) and Teflon® needles are available for smaller children, but steel needles 
appear to correlate with fewer catheter obstructions, despite a lack of controlled studies in this 
area of concern.  Longer needles may need to be used for adolescents or if there are indications 
of frequent catheter issues (Kordonouri et al., 2011).  
 Despite the advantages related to CSII, some children and adolescents and their families  
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opt to discontinue therapy.  An eight year longitudinal study of pump use durability by Wood et 
al. (2006) demonstrated that the main reasons for returning to MDIs were serious problems such 
as DKA, missed boluses, infusion site problems, and a phenomenon referred to as diabetes 
burnout, describing fatigue with site changes, glucose monitoring, bolusing, and dietary 
management.  A small number of subjects in the cohort pointed to concerns over weight gain and 
body image as their reasons for discontinuing CSII.  The study concluded that, since 80% of the 
population maintained CSII therapy for the duration of the study, additional individual and 
family support could benefit those identified as having concerns.   
Type 1 Diabetes in Adolescence  
 Adolescence is a stage of rapid physical and emotional change characterized by increases 
in physical, emotional, and intellectual maturity.  During this period, adolescents are struggling 
with issues of identity, autonomy, achievement and intimacy.  They are continually challenged 
with making decisions regarding school, peers, sexuality, drugs and alcohol, lifestyle, self-
esteem, and future life choices.  Chronic illnesses, such as T1DM, add another dimension with 
challenges that can often conflict with developmental tasks, especially the pursuit of 
independence and peer acceptance (Comeaux & Jaser, 2010; Silverstein et al., 2005).   
Age and Development 
 Although there are varying chronological definitions, adolescence generally includes 
children between the 12 and 19 years of age (Keough, Sullivan-Bolyai, Crawford, Schilling, & 
Dixon, 2011).  Realistically, developmental age is more of a concern than absolute chronological 
age since there is some variation in achievement of developmental tasks.  The period of 
adolescence is difficult in terms of diabetes management as physical and motor skill 
development often occur earlier than the emotional and cognitive maturity needed to manage  
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T1DM effectively (Silverstein et al., 2005).  
 In terms of physical development, adolescents experience rapid growth, including  
the development of secondary sexual characteristics, and hormonal changes associated with 
puberty.  Increases in body weight, as well as surges in growth hormone and hormones related to 
menarche contribute to insulin resistance that can diminish metabolic control (Comeaux & Jaser, 
2010; Dolye, Steffen, & Tamborlane, 2005).  Fine motor skills continue to develop, allowing 
adolescents to competently complete tasks associated with diabetes management, such as blood 
glucose testing and manipulation of CSII devices.  However, this skill level can be deceiving and 
easily confused with the adolescent having the cognitive capability to self-manage T1DM 
(Keough et al., 2011).  Problem-solving ability develops throughout this period, with a gradual 
development of abstract thinking that peaks in late adolescence.  Comeaux and Jaser (2010) 
pointed out that, although the ability to problem-solve increases the adolescent’s ability to self-
manage, their social cognitive skills are generally less mature.  Thus, adolescents sometimes fail 
to apply problem-solving skills due to competing social interests and an urge to fit in with peers.  
Comeaux and Jaser (2010) further discussed these influences and illustrated that the combination 
of the adolescent perception of invincibility and concern with negative reactions from their peers 
has been linked to poor compliance with diabetes regimens in social situations, higher levels of 
stress regarding the disease, and less metabolic control.  For example, an adolescent may be less 
likely to check blood sugar or administer a bolus at a party if he or she thinks friends are 
watching, for fear of being different from peers.  Additionally, adolescents face pressure from 
peers regarding experimentation with alcohol and illicit drugs that could be detrimental to 
metabolic control and life in general (Comeaux & Jaser, 2010).   
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Parent-Child Relationships and Autonomy 
 A common theme in adolescence is the struggle for identity and independence.  
 Conflicts between parents and children are a common feature of adolescence, and the presence 
of T1DM further complicates these situations.  As previously discussed, it is essential for parents 
to remain involved with diabetes management until adolescents have attained the ability to 
problem-solve effectively, and studies have shown a correlation between continued parental 
involvement and better metabolic control (Comeaux & Jaser, 2010; Keough et al., 2011; 
Silverstein et al., 2005).  However, rigid control can actually hinder development of a broader 
sense of autonomy (Comeaux & Jaser, 2010).  The challenge is to find an appropriate level of 
shared responsibility based on the individual adolescent’s cognitive and emotional maturity.   
The Adolescent Experience with T1DM and CSII 
 The majority of research regarding adolescents focuses on various aspects of quality of 
life with T1DM, comparisons of CSII to MDIs, and issues affecting metabolic control.  In their 
review of 49 qualitative and quantitative studies, Comeaux and Jaser (2010) explained that much 
of the available literature predates the availability of long-acting analogs and that few studies 
focus exclusively on adolescents.  Thus, the available literature does not demonstrate the 
potential benefits of basal/bolus regimens.  Indeed, this literature review has reflected that most 
research regarding adolescents peaked in 2005 to 2006.  As such, there are studies that have 
indicated that CSII increases quality of life (QoL) and some that have demonstrated no 
significant improvement over MDIs (Brutomesso et al., 2009; Comeaux & Jaser, 2010; Shalitin 
& Philip, 2008). 
Quality of Life    
A recent qualitative review of the experiences of children and their parents revealed that  
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studies have focused mainly on introduction to CSII, transition from MDIs, advantages and 
disadvantages of CSII, and impact on quality of life (Alsaleh, Smith, & Taylor, 2012).  Their 
review demonstrated that families typically chose CSII in hopes of improved metabolic control 
and greater flexibility and that they generally experienced increases in QoL.  The review further 
illustrated the lack of qualitative and quantitative research in this area as only six studies were 
reviewed.  Only one study focused solely on the experience of children and CSII.  The study, 
following the experiences of young girls, ages 7 to 15 years, examined their views and concerns 
regarding CSII.  The girls expressed satisfaction with increased flexibility in their regimens as 
well as improved health and fewer injections.  Their concerns encompassed the practical 
difficulties with pump use, such as programming, failure and site issues, as well as cosmetic 
concerns over the visibility of the pump.  Despite the drawbacks, all of the girls involved in the 
study opted to stay on CSII (Alsaleh et al., 2012).  Alsaleh et al. (2012) concluded a need for 
more research examining how children and their parents feel about CSII in the context of their 
daily lives and activities, specifically those that compare the perspectives of parents and children.   
 Faulkner (2010) performed a descriptive study of cardiovascular fitness and QoL for 
adolescents with diabetes.  Her literature review revealed that, although clinical trials have 
shown that adolescent perceptions of QoL can be reliably measured with available instruments, 
research involving cardiovascular fitness had failed to discuss a relationship to QoL.  Her study 
concluded that there are adequate associations between fitness, metabolic control, and health 
perception to recommend encouragement of regular physical activity and inclusion of exercise in 
treatment regimens.  She noted that adolescents who were more physically active perceived 
themselves as healthier, demonstrated greater academic abilities and overall self-worth, and 
reported more positive views of generic QoL.   
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 The randomized controlled trial carried out by D’hooge et al. (2011) evaluated the impact 
of a 20-week program of combined resistance and cardiovascular training on metabolic control, 
QoL, and cardiovascular fitness.  Though the study had some methodological issues, mostly 
related to a small sample size (n=16) and low participation, there were significant increases in 
physical fitness and reports of improved general health, role emotional, and vitality in terms of 
QoL.  The authors concluded that these improvements, in conjunction with a noted decrease in 
daily insulin requirements, confirm that vigorous exercise contributes to QoL for adolescents 
with T1DM and should be encouraged.   
Issues Specific to Athletes with T1DM   
Athletes with T1DM indeed face unique challenges when compared to peers without 
diabetes.  Hornsby and Chetlin (2005) presented a management plan for competitive athletes 
with diabetes.  The authors explained that although most research regarding diabetes has focused 
on moderate-intensity aerobic activity, the majority of competitive sports are anaerobic in nature, 
relying on brief bursts of energy.  Anaerobic metabolism can only be sustained for a few minutes 
at a time, compared with the aerobic metabolism involved in lower intensity exercise.  Thus, 
healthcare providers and coaches must take this into consideration when making 
recommendations regarding blood glucose levels, diet, and insulin therapy.  Hornsby and Chetlin 
(2005) pointed out that motivation to participate in competitive sports generally has little to do 
with health benefits, especially where children and adolescents are concerned.  Young people are 
more likely to play sports for fun, friendship, appearance, excitement associated with 
competition, a sense of achievement, and skill development.  Individuals with T1DM may seek 
out sports as a way to compensate socially and feel more accepted by their peers.  Additionally, 
high school athletes may be motivated by incentives such as college scholarships and eventually  
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professional sports contracts and endorsements.   
 A common aspiration for athletes is to improve performance.  Athletes often resort to 
extreme measures to achieve their goals, including using dangerous dietary measures and 
performance-enhancing supplements.  These practices can be especially detrimental in 
individuals with T1DM who are willing to sacrifice metabolic control and overall health for 
competitive gains (Hornsby & Chetlin, 2005).  Thus, it is vital for healthcare providers to 
understand these measures and their potential impact to counsel athletes appropriately.   
Management for athletes with T1DM must focus on predicting blood glucose responses 
to training and competition and must be individualized.  The minor injuries athletes regularly 
experience can pose a particular threat to athletes with T1DM because of increased susceptibility 
to infection, especially when glucose is poorly controlled.  Typical athletic treatment modalities, 
such as ice, heat, or massage can affect insulin absorption and must be used with care.  Those 
with T1DM can safely participate in competitive sports, provided they maintain good metabolic 
control and do not have long-term complications.  A comprehensive medical history and physical 
examination to identify specific risks before allowing participation is necessary (Hornsby & 
Chetlin, 2005).   
To date, there have been no studies regarding the experiences of adolescent athletes with 
T1DM using CSII.  The literature has shown a positive correlation between fitness and QoL, and 
has demonstrated that CSII provides increased flexibility in T1DM management and lifestyle.  
The media present success stories of college and professional athletes who successfully manage 
T1DM.  However, the unique challenges of adolescents in the context of managing T1DM while 
playing competitive sports have not been addressed.  Evaluation of these adolescents’ 
perceptions may help healthcare professionals better understand their experiences and provide  
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better support and guidance.   
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Chapter Three: Methodology 
This descriptive qualitative study examined the experiences of adolescent athletes using 
CSII as their primary insulin delivery method.  This chapter includes an overview of the setting 
and sample for the study.  This is followed by a discussion of the methods and procedures for the 
study, including the protection of human subjects. 
Setting and Sample 
 This was a pilot qualitative study with the goal of exploring and describing the 
experiences of adolescent athletes using CSII.  Considering the paucity of previous research 
regarding this distinct population and the narrow scope of the study, a small sample size is 
appropriate as the focus is on the quality of information obtained (Burns & Grove, 2011a).  
Purposive sampling was used to select four adolescent participants.  Participants were recruited 
from the Division of Endocrinology at Nemours Children’s Clinic in Jacksonville, Florida 
(NCC-J).  The clinic houses six pediatric endocrinologists, as well as nurse practitioners, 
nutritionists, a clinical social worker, and certified diabetes educators (The Nemours Foundation, 
2012).  The chair of this University of North Florida Brooks College of Health thesis committee 
is also an employee in the Division of Endocrinology at NCC-J.   
To participate in the study individuals were required to meet the following inclusion 
criteria: between 13 and 18 years of age, diagnosed with T1DM for at least six months, able to 
speak English fluently, using CSII as their primary insulin delivery method, currently in good to 
excellent glycemic control (HgbA1C ≤ 7.5%), and must have participated in organized sports 
activities during the spring or summer of 2012.  Adolescents who had cognitive impairments or 
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serious concurrent conditions were excluded for the purpose of maintaining a focus on T1DM.  
An additional exclusion criterion was that the adolescent must not have been participating in 
another study at NCC-J.  
Procedure 
  Qualified participants were invited into this qualitative descriptive study by a nurse 
practitioner who is familiar with the patient population.  Names of potential participants were 
solicited from clinic physicians.  Once participants agreed to interviews and consents and assents 
obtained (see Appendix A), a time, date, and location of the interview was established.  
Demographic information pertinent to the study was collected for all participants via interview.  
Demographic questions and results are shown in Appendix B.   
A face-to-face semi-structured interview focused on athletic participation and 
performance.  Open-ended questions and prompts were employed to elicit the distinctive 
experiences, feelings, and attitudes of the adolescent participants and their parents (see Appendix 
C).  The interviews were intended to be conducted in an area separate from the clinic exam 
rooms to prevent interference with clinic patient flow.  However, in order to ensure participant 
comfort and convenience, interviews were administered at a location of their choosing and lasted 
no longer than 60 minutes.  Upon completion of the interview, participants were given a $10 gift 
card as compensation for their time.  Interviews were audio recorded, dated, and transcribed 
verbatim by the investigator within a few days.  Field notes were taken as needed for recording 
additional significant information before or after the scheduled interview.   
Design and Data Analysis  
Qualitative descriptive inquiry method is used to explore and describe 
 phenomenon and allows the researcher to “stay closer to their data and the surface of words and 
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events” (Sandelowski, 2000, p. 336).  This method provided a rich description of the 
adolescents’ experiences expressed in their own words.  Data analysis occurred simultaneously 
with data collection.  The transcribed interviews were read several times, first like a story, then 
over again to gain a sense of the experience.  Consistent with thematic analysis, transcriptions 
and field notes were analyzed to capture the meanings and context of the participants’ 
experiences (Mauk, 2009a).  Line-by-line analysis of the data began, starting with open coding.  
During this step, participants’ words and phrases were labeled with codes.  Following open 
coding, interview questions were re-evaluated to determine where additional information was 
needed.  In addition, the researcher debriefed with a thesis committee member after coding each 
interview to validate interpretation of the participants’ experiences (Burns & Grove, 2011b; 
Mauk, 2009b).  Since data collection and analysis were occurring simultaneously, the researcher 
explored and validated emerging themes developed from early interviews by posing questions 
about them to participants in later interviews.  Additionally, after each successive interview, the 
researcher re-analyzed previous interviews and sometimes clarified or revised existing codes.  
After the fourth interview, the researcher and committee member concluded that coding had 
become redundant, with no significant new information, and decided to end data collection.  The 
researcher then compiled codes into a master list in preparation for the next step, axial coding, 
which entailed grouping similar or related codes under a working theme or category in a non-
hierarchal fashion.  The researcher reviewed these working themes with both committee 
members and refined them multiple times.  
The researcher strove to keep the study participant-oriented rather than  
researcher-imposed.  Responses were monitored by maintaining a journal of reflexive thoughts 
and debriefing with a thesis committee member to ensure researcher objectivity.  Credibility, 
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confirmability, dependability, and transferability were addressed through peer debriefing, 
detailed interviews, and clear explanation of the boundaries and limitations of the study (Mauk, 
2009b).   
Protection of Participants 
 Approval for this study was obtained from the Institutional Review Boards (IRBs) of the 
University of North Florida (see Appendix D) and NCC-J (see Appendix E).  Written informed 
consent was required for all participants and was signed by the parent or legal guardian for 
participants under 18 years of age.  Additionally, assent was required for participants under 18 
years of age.  Consent and assent forms are shown in Appendix A.  To preserve anonymity, each 
participant was assigned a participant number and a pseudonym.  While the initial intent was to 
focus solely on responses from the adolescent participants, following the first interview it 
became clear that parent responses needed to be included.  Therefore, following amended IRB 
approval, parents were informed that, if they chose to be present for the interview, their 
responses would be considered as well.  At the initiation of the interviews, participants were 
briefed on the interview procedure, including that the interview would be audio recorded, and 
informed that they had the right to withdraw from the study at any time and the right to refuse to 
answer any interview question.  All recorded data was destroyed once transcribed.  Identifying 
information was shared only with the UNF graduate student conducting the interviews and the 
faculty chair who facilitated participant recruitment.  
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Chapter Four: Results 
The purpose of this study was to explore and describe the experiences of adolescent 
athletes using CSII, with the intent of accurately representing their issues and concerns.  The 
primary investigator contacted six eligible adolescents, recruited during their diabetes clinic visit, 
by telephone.  Two did not return a phone call.  Ultimately, four adolescents participated in face-
to-face interviews with their mothers present at a location of their choice.  All participants were 
receiving care at the same Northeast Florida pediatric endocrinology clinic.  Interviews lasted an 
average of 52 minutes, the shortest being just over 30 minutes and the longest 62 minutes. 
  Of the four participants, two were female and two were male.  Three of the participants (Ryan, 
Rose, and Marie) were 13-years-old, and one (Rob) was 15-years-old.  All four participants were 
Caucasian and were of middle to upper socioeconomic status.  All participants had health care 
coverage: Three covered by private insurance and one by Medicaid.  Three participants were 
diagnosed in 2006 and one in 2011.  All had been using CSII for at least one year; one for five 
years, one for 18 months, one for six years, and one for four years.  One adolescent used the 
Minimed Paradigm® pump, one used the Omnipod®, and two used the Animas® pump.  
HgbA1C results at the time of recruitment ranged from 6.7% to 7.2%.  All of the adolescents had 
recent experience participating in athletics while using CSII.  Sports participation included 
soccer, indoor volleyball, tennis, full-contact football, softball, and rugby, as well as various 
recreational activities, including water activities.  A full account of demographic information is 
included in Appendix B.  Four core themes emerged from the analysis of the transcriptions, 
along with multiple subthemes: protecting the pump and infusion site, dealing with the highs and 
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lows, maximizing participation and performance, and keeping watch.  A discussion of the themes 
with examples of each follows.  It is important to note that the goal of tight blood glycemic 
control is a common thread through each of the themes.  
Protecting the Pump and Infusion Site 
 Choosing and changing infusion sites, especially while participating in sports was a 
common issue for these athletes.  Participants reported changing sites every three days as 
recommended unless the site was lost prematurely.  With the exception of Marie, all of the 
participants cited protecting the pump infusion site during activity as their biggest challenge.  
They all mentioned modifying the location to prevent losing the infusion site during play.  
Marie’s mother reported that her position when playing softball made finding a suitable site 
problematic:  
Well, and she’s a catcher…so, she squats a lot.  The only thing we had to modify  
is…she used to could wear it in the top of her butt, but she catches…she doesn’t  
have enough fat there…She initially wore it on the inside of her thigh, but she  
doesn’t have enough fat…on her legs and butt to put it…but she doesn’t have any  
issues as long as we get it in her stomach or her back where her pants don’t rub.  
They finally decided to rotate sites on her arms, back, and stomach.  Her mother went on to add 
that since Marie tends to lose her sites due to sweating, they modified a transparent dressing to fit 
over the site and allow for disconnecting the pump tubing.  Ryan and Rob both considered losing 
their pump sites during play to be a significant issue.  Ryan stated his tactic when playing soccer 
was to “just try to stay on my feet…not get on the ground” and “If the ball’s coming at me, I try 
to hit it with the other side.”  He also used an additional adhesive dressing that helps the site 
adhere.  His mother added that, when playing tackle football, they found that his low back was 
best for protecting the site, 
 explaining:  
So, we actually ended up using…the stomach or the back more…you know the  
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backside…that had the least interference with anything, but those pants…because their 
pants are real tight, so if you had it on your leg you run the risk of it just…putting those 
pants on (motioning the site ripping off)…And we’ve found, with teenage boys as they 
start maturing, they tend to be…sweatier or more hair on their legs.  Things like that can 
cause the sites not to adhere well to the skin. 
 
Additionally, she noted that water activities would usually necessitate a site change.  Rob 
reported that he prevented having sites “ripped out”  when playing soccer by positioning it on his 
buttocks, noting that, “it came out more when it was on my back than on my butt because on my 
butt my sliders [compression shorts] hold it in.”  Rose, who played volleyball and tennis and 
used the OmniPod®, generally wore her pod on her abdomen, but chose to position her pod on 
her hip when participating:  
If you slide on the floor to catch the ball, where it is if maybe it might come off or  
something like that…or in tennis, if like, the ball hits it…’cause I’ve had some  
balls hit me before…and I’ve gone low.  I only put it on my hip for sports.  
When asked about using an additional adhesive, she stated, “No, OmniPod is very good about 
staying on.” 
 Another significant issue was protecting the device itself.  Since they were involved in 
contact sports, Rob and Ryan chose to disconnect their pumps completely, for up to two hours, 
during practices and games to prevent damage.  For Rob, that meant placing his pump in his 
sports bag in the locker room during rugby or soccer and reconnecting at halftime.  Ryan, on the 
other hand, would hand his pump off to his parents “because it’s one of the ones that clips to 
your waist and I don’t wanna be knocking it off or it falling off when I’m running.”  His parents 
would locate him at halftime to allow him to reconnect if necessary.  Since Rose used the 
OmniPod®, she simply kept her PDM in her purse or sports bag as the pod supplies her insulin.  
Of the four, Marie was the only participant who has worn her pump continuously during 
participation.  For protection when playing softball or volleyball, she stated, “I usually will put it 
in the back pocket of my pants…and I don’t have a problem.”  In addition, Marie’s mother 
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reported that she used a thick rubber pump “skin” and a screen guard because “we did have a 
huge problem with screens getting really scratched up, getting cracked…they would send us a 
new one and we’d mail the old one back.”  Referencing the pump skin, she noted, “For their 
warranty to be covered, they have to wear it.”   
Dealing with the Highs and Lows 
  The second theme that emerged entails preventing and managing acute complications, 
namely hyperglycemia and hypoglycemia, and the various approaches that the participants used.  
This theme, along with subthemes, arose from responses related to eating and insulin doses.  
Since these complications can preclude participation in athletic activities, athletes must closely 
monitor blood glucose prior to and during activity, and must take appropriate steps to avoid 
highs and lows.   
Preventing Lows During and After Activity 
Ryan reported that he would test his glucose prior to activity, at halftime, and after games 
or practices.  He stated, “To try to prevent from getting a low blood sugar…eat my normal 
breakfast…and half a bottle of Gatorade® before I play...twelve grams of carbs, maybe?”  His 
mother elaborated that they aimed for a blood glucose level of 150 mg/dl prior to activity and 
corrected elevated glucose accordingly.  Since he was disconnecting until halftime, they would 
also give half of what his basal rate would have been.   
Rose did not suspend her basal insulin during games or practices, but instead decreased to 
70%-80% of her usual rate as she wore the OmniPod®.  She preferred to begin her tennis 
matches with her blood glucose around 200 mg/dl.  She stated, “You’re supposed to start at 150, 
but it’s [my experience] showed that I need to be higher.”  She would “eat something substantial, 
like a peanut butter sandwich” prior to volleyball games or practice.  Her mother added that 
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sometimes before tennis practices she would have a peanut butter smoothie from a local chain 
restaurant with modified ingredients “made special for her, with only 57 carbs.”   
Marie also began participation above 100 mg/dl, recounting, “…usually like 100 to 180.  
120-180ish…somewhere in between there is probably about where I would be at.”  Her mother 
followed with, “Usually above 120.  She doesn’t run high very often, so...she kinda plays it by 
how she’s feeling…is she gonna start that day?  She typically does start [referring to being in the 
starting lineup].”  Marie and her mother reported that they have learned to prevent lows during 
activity by including a protein-rich snack beforehand and bolusing for only half of the 
carbohydrates, especially if her blood glucose is already below 100 mg/dl.  Similar to Rose, 
Marie reported her typical pre-activity snack was “peanut butter and jelly probably because of 
the peanuts.”  Further, her mother reported that, “We try to eat only whole wheat bread …we’ve 
seen a more consistent blood glucose with that.”   
Rob, the key informant for this particular subject, disconnected for approximately 80 
minutes when playing soccer or rugby.  He reported checking his blood glucose 10 minutes prior 
to activity and using 75% of his normal correction dose, ideally starting at “150 to 160ish.”  He 
did not play if his blood glucose exceeded 315 mg/dl.  His mother recalled an instance where she 
had to keep him out of a game, stating, “He was really high, like 400 high…and I didn’t let him 
play.  I think it did go down and…he did 
play toward the end of the game.”  Rob conveyed that his preferred pre-activity snack is a  
Clif® bar, stating, “I’ll have one of those anyway before I start…like 27 carbs…and a 
Gatorade® Prime…like 7 to 10.”  Like Marie, he only gave himself a bolus for half of the 
carbohydrates consumed.  When he checked his blood glucose at halftime, he would consume 
regular Gatorade if he was “getting low or felt low.”  In addition, he would ensure hydration  
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prior to activity and “eat healthier that day, like not so much greasy foods.” 
Being Prepared 
A key factor in preventing or managing highs and lows was having the appropriate 
equipment available.  Ryan and his mother briefly discussed having an emergency kit in a 
waterproof box.  Rose articulated that, after having a few pump malfunctions, she learned that 
she needed to give herself an injection of insulin and hydrate if her glucose is very high.  She 
demonstrated that, in addition to her glucagon and an insulin pen, she carries extra supplies in 
her purse at all times, duplicated in all of her sports bags:  
I have this [in a wallet], which has a kit in it, and then my pricker [lancet] is in  
there, and I have a medic alert card.  And then I have some glucose gel, a Tiger  
Milk® bar, and three peppermints, my alcohol swabs, extra needles for my pen,  
my extra needles for my pricker, and then extra batteries for my PDM.  And then I  
always have a water in my purse for if I’m high, and if I’m low, I have crackers  
that I change out—always 15 carbs. And then I have a juice…and I have an extra  
pod.  
Rose also proudly mentioned that she figured out a backup plan for insulin:  
[When] my pod is running low on insulin, but I don’t really have enough insulin  
to change it, or I don’t wanna have to change it at that moment…I’ll draw up the  
insulin I need in my pen for the bolus and I’ll give myself that…so that I can keep  
my basal rate going and not use up all the insulin in my pump.  Yes, I made that  
up myself.  
Marie’s mother stated that Marie carries her glucagon at all times, as well as an insulin  
pen, “in case there is a pump malfunction and she’s high.”  In addition, they ensured that there 
was juice and snacks in a shed near the softball field.  Rob admitted that he did not typically 
carry his glucagon, but his mother clarified that either he had one in his sports bag or his parents 
or the team athletic trainer had one.  However, Rob is the only participant who cannot carry his 
glucagon on him at school.  His mother said, “It’s locked in a drawer in the nurse’s office.”  He 
reported that along with his glucose meter, he also carries an extra infusion set, “and then there’s 
a couple in the car.”  
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Early Morning Lows 
Each of the participants or parents expressed concern with experiencing hypoglycemia in 
the early morning hours following athletic participation.  Ryan’s mother brought up the topic 
when discussing their experience with managing his blood glucose while playing a new sport:  
We had a hard time with tackle football…getting the blood sugars right.  But, we  
found that right after…his blood sugar may be 300, but if we corrected he would  
crash into the night.  It’s almost like the adrenaline…pumped his blood sugar  
up…I guess or something. 
While discussing eating after activity, Rose mentioned that “A few times at nighttime, it’ll be 
like many, like hours after, and Mom will come and check me at 2 a.m. and I’ll be crashed.”  
Like Ryan’s mother, Rose’s mother implicated adrenaline as a catalyst for crashing, but also 
stated:  
Because this is the biggest concern…the after activity. It’s really hard to gauge on the 
sports.  I’ll go in at one, two o’clock in the morning and she’ll be 33 or 43…or, you know 
when the blood sugar does that drastic drop with that post activity thing. Some athletes 
can figure out exactly when that’s going to happen, and  I think as she gets older we’ll 
have a better picture, but part of it is hormones. Puberty comes in there and you have to 
say, “Is this a nighttime puberty thing? What hormones are going on?”  But, why we quit 
suspending [her basal insulin] was that reason—because of the crash later. 
Further, she explained: 
I determined that if we kept suspending and no insulin, that’s when we were  
crashing at one in the morning. They need some insulin…because it’s pulling too  
much from the other sources if you don’t do something.  When we did the 70 to  
80% [basal rate reduction]...once again we go by whatever we’re doing that  
day…then we don’t seem to have those crashes.  
 
She later stated that she feels that this phenomenon is a major factor preventing the artificial 
pancreas from coming to fruition.  Marie also reported episodes of early morning hypoglycemia, 
declaring:  
Not very often, but when it does, I hate ‘em!  …I feel really shaky.  You have to wake 
up…go in there and do it [check blood glucose], so I always wake up Mom or Dad and 
tell them I’m checking. 
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Rob and his mother expressed the most concern over this phenomenon.  While discussing 
checking blood glucose during activity and describing his hypoglycemia warning signs, his 
mother interjected, “when he’s awake.”  She went on to explain that for the past several months 
he has not been waking up for school mornings after intense practices.  She reported multiple 
instances of checking him and finding his blood glucose under 50 mg/dl:   
So, that happens so much that I buy a case of juice boxes…to keep by his bed.  We’ve 
talked to the doctors, and we’ve adjusted and we…we have not solved the problem.  So, 
he makes sure he eats a lot…adjusts his basal rate, but still…every morning after he has a 
practice...I stick a juice box in his mouth…and he doesn’t remember any of it.  
 
Rob followed up, explaining, “For that night I’ll lower my basal by like 30 to 40%, and like, that 
night I was 47…I had 2 brownies and another [Clif®] bar before I went to sleep.”  With tears in 
her eyes, his mother expressed great concern that she will have to resort to giving glucagon at 
some point.    
Decision-Making 
Another subtheme is decision-making approaches.  While processes such as carbohydrate 
counting were, as a rule, done according to recommended techniques, adjusting the insulin 
regimen entailed more creativity on the part of the adolescents and their parents.  They used 
terms such as “guesstimating,” “trial and error,” and “fine tuning” to describe calculating 
correction doses.  Ryan’s mother indicated, “We kinda…do a guesstimate sometimes…’cause 
we don’t want him to drop while he’s playing…sort of play around with the numbers a little bit 
with every sport.”  Marie’s mother talked about figuring out basal settings, stating, “You can fine 
tune that…I mean you could set a different basal every half hour if you wanted to.”  Rob had 
trouble pinpointing how he determined he would only make a 75% correction prior to 
participation:  
I just kinda came up with it.  It works.  I knew that a full dose would probably too much 
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 and half would probably keep me high.  That was just kinda in the middle.  That’s just 
always worked.  It’s always kept me like 130ish, 120ish. 
 
Another decision-making approach demonstrated by all participants was making 
experienced-based adjustments.  Many of the participants/parents mentioned that, based on prior 
experiences, they avoided giving a full correction dose during or after games or practices.  Ryan 
explained:  
Well, before I play I test it [blood glucose]…about one time…and then at halftime 
usually, I test it again just to see where I’m at and if its high I do like, half the normal 
correction that I would…And then after the game I test it just to see where I’m at and if 
it’s high, I don’t do a full correction ‘cause I know I usually drop low after I play. 
His mother elaborated that if his blood glucose was high after activity and they did a full 
correction he would “crash all day and into the night.”  Calling this a “false high,” she stated that 
they usually opted to “wait a couple hours and then check it again to see if his number is 
normal… and  it [blood glucose] always would come back down to normal range after a couple 
hours.”  Additionally, if he was hungry after activity, they would bolus for the carbs consumed, 
omitting the high dose correction.  Rose’s mother echoed Ryan’s mother’s comment about 
avoiding immediate high correction and explained that they “kind of let it shift…then go to 
dinner, and we don’t really correct all the way down to 100 for a few hours…and then at bedtime 
correct to 150.”   
Maximizing Participation and Performance 
The overall goal for these athletes is to maximize participation in their chosen sport(s) 
and to maintain peak performance.  All participants were involved in more than one sport.  
Maximizing participation and performance involves finding strategies, which may vary by sport, 
to avoid interruptions in games and practices.  Additionally, it involves nutrition, hydration, and 
finding strategies to avoid interruption in games and practices.  This theme emerged through the 
general tone of the interviews and is discussed next with examples.  
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Overwhelmingly, these athletes demonstrated positive attitudes regarding diabetes and 
wearing an insulin pump.  Ryan asserted, “Just don’t let it stop you.  You can still do everything 
else that everyone else does…you just have one extra step.”  Marie stated, “You can live your 
life normally…it’s not anything to stop you.  Just live a normal life.  If you beat it mentally, you 
can beat it physically.”  When asked how much he thinks about his diabetes, Rob stated, “I have 
to check my blood sugar before I eat, and then I just…go on my way.”  Rose, discussing her 
feelings about her insulin pump, expressed that it gives her a feeling of “freedom.”  Their parents 
echoed these views.  In addition to the participants’ views, Marie’s mother stated, “It’s made her 
be able to play more intensely than I think she would have been able to play…because you’ve 
got much tighter control…and a short window if there is a problem.” 
The athletes were asked to compare their experiences with using injections to the  
insulin pump.  The only disadvantage described was, again, the prospect of losing the site  
during activity.  Most commented on the increased ease of use and convenience compared to 
injections.  Ryan stated, “It’s good…at halftime you don’t have to draw up a shot and put it in 
real quick…push a couple buttons on the pump…you don’t have to be constantly giving yourself 
a shot in a different spot.”  His mother cited the time factor, stating, “You’re not out there trying 
to hurry up at halftime and calculate and figure and draw it up and stick it in….it was kinda 
hectic and frantic, so it’s been a lot easier.”  Like Ryan, Marie alluded to convenience: “It 
doesn’t take as long as it would to…clean it, inject it, then have to put my jersey back in my 
pants.”  Similarly, Rob stated, “It’s just like easier…I don’t have to get the alcohol swab, and 
wipe, and wait for it to dry…and then pack everything back up.”  Rose expressed a feeling of 
reassurance with her insulin pump: “With the needles you don’t know…how much…that it’s 
going to give you that much, while with the pump you know that every hour…like when I can 
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hear the actual little click.”  She referred to the clicking sound made by the pod as her “white 
noise,” noting that if she does not hear it, she begins to wonder if there is a problem with the 
system.  In addition, she cited privacy as a major advantage over injections, stating, “You don’t 
have to lift up your shirt…’cause I do it on my stomach” and “It’s very fast…they  
don’t know what I’m doing.”   
Not Being Different 
For these athletes, keeping up with peers, especially when involved in athletics, is a 
necessity.  Furthermore, issues that would draw negative attention to them or make them feel 
different were a demonstrated concern for the participants.  In general, the participants reported 
responses from coaches or teammates to them playing with an insulin pump were neutral.  They 
did not bring up the topic unless asked directly.  Ryan explained that he is “used to it,” and 
stated, “It doesn’t bother me” when teammates asked him about testing blood glucose.  He also 
noted that he feels he usually keeps up well with peers, “but if I’m having a low blood sugar then 
I kind of get behind them a little bit.”  When asked about missing playing time, he replied, “Oh, 
well, sometimes I miss some playing time…but in a way it’s a good thing ‘cause it’ll be back to 
normal.”  Rose revealed a bit more anxiety related to negative attention, sharing an instance 
when she had to leave the tennis court due to hypoglycemia:  
Yeah, but it is definitely hard…I don’t wanna have to…because one time I actually did 
have a match where I just had to walk off the court, and the guy [opponent] just kinda 
was…I don’t think he knew what was happening.  So, he just sat there on the court and I 
felt really bad…and he didn’t know why.  But, I’ll finally be like, ok, ok, ok, I’ll go, but 
I’ll just eat and go back on the court.  I won’t give myself a few minutes…that’s 
definitely my thing.  
 
Her mother explained that she feels that, “The hardest thing for this age…and sports 
especially…is it’s hard to wanna take a break and bring attention brought to yourself, and you’re 
hesitant to.”  For Marie, the main source of negative attention came from umpires questioning 
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her about the pump, stating, “Yeah, they just wait until the middle of the game…they don’t ask 
before.  And I tell them, and they’re like, ‘Oh, I thought it was an iPod’ (laughing).”  Rob briefly 
mentioned that it was important to him that tasks to manage blood glucose during a game be 
“discreet,” but when asked to elaborate further, he shrugged his shoulders and said, “It’s just not 
like this big thing.”  
Keeping Watch 
A third theme that emerged, primarily from the parent responses, was a feeling of others 
watching over the athlete.  The concept of keeping watch was not limited to  
parents, but also included coaches, friends, and athletic trainers.  Discussion of this  
theme with examples follows.  
 The narratives illustrate that parents and adolescents share responsibility for insulin pump 
management at varying levels.  Use of the word we usually reflected a division of ownership of 
and responsibility for the pump and related processes.  When demonstrating that the adolescent 
was responsible, the mothers tended to use the term he or she instead.  However, when 
discussing using advanced pump settings, Ryan’s mother stated, “You know, as a parent, with 
your pump and stuff, at least on the pump he’s using.”  Ryan further evidenced his mother’s 
dominant role in managing the pump when he admitted, “She usually does all the changing 
around,” regarding basal insulin settings.  In sharp contrast, Rob’s mother rarely used the word 
we when referring to managing the pump, suggesting that Rob was primarily responsible.  Rose’s 
mother, on the other hand, specifically stated, “It is a team.”  Responsibility for the pump did not 
seem directly influenced by chronologic age as Rose, the same age as Ryan, maintains control of 
her own OmniPod® with the PDM, as does Marie with her Animas® pump.  
It became clear that, regardless of the athlete’s level of autonomy, their primary caregiver  
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continued supervision of processes related to the pump and diabetes.  Ryan’s mother disclosed 
that she and his father supervised all activities related to his insulin pump and were active in his 
decision-making.  Rose’s parents have allowed her to have primary control of her PDM and 
make most decisions, but her mother reported they are “standing and watching” and will 
intervene when necessary.  She discussed her thought process regarding giving Rose 
responsibility:  
She’s got a handle on it.  She knows what to do.  And she knows the consequences that if 
she doesn’t do it right, she’s not gonna get to play.  And that’s her drive!  I think that 
since she is so responsible, I am trying to let go a little bit at a time…and the reason I do 
relinquish and give her so much control is because she’s gonna have to do it when she 
leaves…I don’t think that if I baby her, I’m doing her any favors.  
 
She further explained that there are times when Rose will still ask her to help with diabetes-
related tasks, stating, “It is a team, but I think that I give her a lot of leeway…trust her 
judgment.”  Marie’s mother explained that she still makes changes to the basal rates on the 
insulin pump and occasionally helps with site insertions, but insists on Marie taking an active 
role in management:  
She did all her own injections from the time she left…her initial hospitalization.  We 
made her responsibility to learn…We’ve made her really learn…to be able to carb count 
on her own…to check her blood sugar…She knows that if I’m not there when she calls 
me and says “I’m 450” the next words out of her mouth are “I have trace ketones” or “I 
have no ketones.”  She already knows what to do.  She’s been doing her own sites for 
maybe the past three years.  From day one, we started letting the majority of that be her 
responsibility.  I think the sooner they start to learn to do that [manage the insulin pump] 
on their own, the better.  They’ve got to be able to live a normal productive life, and I’m 
not going to college with her! 
She further explained that, as a health care professional, she has seen the extremes of giving and 
withholding responsibility, stating, “You can’t let them have it all…kinda have to give that in 
small increments as they mature…what they can handle.”   
Rob, the oldest, was clearly the most independent of the participants and made most 
decisions related to his diabetes, but his mother reported:  
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I’m always harping on him to check it, to check it, to check it…you know?  I can 
remember being across the field motioning to him to check…just reminding 
him…keeping on top of it and everything.  And you know, him being older and being 
gone from home more…I just have to ask him all the time.  “What is your blood sugar?”  
Not just “Is your blood sugar ok?”  It’s just getting him to check his blood sugar on a 
regular basis, which he’s gotten much better about. 
 
While Rob did roll his eyes several times while his mother gave this description, he noted that 
this was helpful at times, “It just like, reminds me…you just get caught up in other things…”  
Rob’s mother explained that she felt comfortable with giving him more responsibility because he 
is mature for his age, also declaring, “Just because he’s a good kid and he doesn’t give me any 
trouble…it probably helps that he’s pretty good at using it [his insulin pump]…instinctively 
knows how to work it all.” 
 The most obvious example of keeping watch was the parent checking blood glucose 
during the night.  As mentioned, each of these athletes have experienced nighttime or early 
morning hypoglycemia.  Ryan’s mother was the first to mention checking blood glucose in the 
middle of the night when discussing hypoglycemia.  Follow up questions were included in later 
interviews.  Rose’s mother reported that she is “OCD” about checking Rose’s blood glucose, 
stating, “We check every three hours.  Sometimes four through the night now, just depending on 
where the number’s at…sometimes God wakes me up…the better controlled and we don’t have 
those crashes during sports.”  She further explained that it was from these early morning checks 
that she was able to figure out that suspending Rose’s basal insulin during sports was not 
working.  Rose occasionally wore a continuous glucose monitor, but asserted:  
I just don’t like wearing it and it’s not 100% accurate.  I still have to do as many pricks as 
the regular.  So, it’s like 100% of what I regularly do plus one.  And it’s not 
automatic…you have to push it and it hurts. 
 
Her mother acknowledged that she understands that wearing two appliances is difficult,  
stating, “I wish she would wear it more…but I’m not the one who has to wear two contraptions... 
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but I miss it at two in the morning.”  Marie’s mother reported that she hardly checks her glucose 
overnight anymore, stating, “No, I need my sleep and so does she.  Now, if we’re having some 
issues and getting up high, I may for three or four nights in a row…at midnight, at three…see 
where we are.”  She also noted that Marie would typically wake and check her glucose and eat if 
she experienced a significant low.   
As previously mentioned, Rob’s mother reported that she began checking on him in the early 
morning hours when it became apparent that he was not waking in time for school the morning 
after participation.  She said, “It’s gotten to where I just wake up every morning and check.”  
Parents Becoming the Expert 
In addition to physically checking on the athlete, keeping watch emerged in parents’ 
initiative, beyond working with the diabetes team, to become the expert on their child’s diabetes.  
For Ryan’s mother, this meant collaborating with other parents.  Rose’s mother reported that she 
has been quite proactive in seeking answers:  
We had to learn a lot on our own.  We were on it.  I was doing research at four o’clock in 
the morning on my iPad…what are we gonna do now? How are we gonna keep her 
healthy?  I talk to Insulet a lot.  I’m on every webinar.  I’m at every local JDRF meeting. 
 
Marie’s parents, both healthcare professionals, had several years of experience with diabetes and 
worked closely with the diabetes team and pump company to develop the best strategies for 
managing her blood glucose during athletics.  In addition, her mother wore an insulin pump for 
one week before Marie initiated use.   
 When asked about education needs, parents reported receiving between 10 and 24 hours 
of diabetes education specifically related to using an insulin pump, including a one-day 
admission to the hospital for initiation of therapy.  For the most part, parents responded that they 
were satisfied with the amount of education provided initially.  However, two parents did suggest 
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that they would like further education regarding using the pump.  Rose’s mother for instance, 
stated: 
Eighty percent of people need a lot more education…with a little bit more guidance, past 
just that initial “here’s the pump, here’s how it works.”  Because our temporary basal 
thing was turned off on our PDM.  We had never used it before, but they had turned it 
off.  I’m like…there’s gotta be a better way than crashing at one in the morning.  Lots of 
things were turned off, and once I started researching, I was like, “we can activate these 
temporary basals…instead of always having to suspend.”  We’re learning more all the 
time…We’re only using only 30%-40% of the capabilities of the pump. 
 
She went on to note that she would like to see: 
A next step education process, like say six months after the pump…for more advanced.  
And I think that’s one thing lacking in the physician’s world. It’s, “let’s just changes the 
basal rate.”  No, let’s don’t change the basal rate …let’s adjust that time and maybe do 
for that activity.  The sports is hard…and that crashing at one or two in the morning, I 
think that could be done away with.  I think that there needs to be a different, maybe a 
whole person [at the clinic] who does nothing but sports…diabetes.  I think that would be 
incredible. 
  
 Marie’s mother stated that, although her daughter has done well with it, “carb counting is what 
they could help them with the most.”  In addition, she stated that educators need to know “you 
can’t go everything sugar-free” and need to spend more time talking about processed food 
because “it makes it easier to do carb counting…but you don’t get really good control with that 
[processed foods]…you just don’t feel great.”    
Parental presence at sports practices and games occurred at varying extents.  Ryan stated 
that his parents were present at all practices and games.  His mother further disclosed (following 
the interview) that his father was one of his coaches and that she would probably not allow him 
to play if this were not the case.  She also stated that, since she and his father are mainly 
responsible for his diabetes management, she did not feel Ryan would be able to deal with an 
emergency if his parents were not present.  This was indeed the extreme example.  Rose also said 
that at least one of her parents was present for tennis practices and games.  Her mother  
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elaborated that she felt comfortable letting Rose attend volleyball practices alone since it was a 
school team, but felt more apprehensive about tennis practices and games outside of school.  For 
Marie, parental attendance at practices and games depended on work schedules, as her mother 
explained, “Usually one of us is there every game…” and for practices, “Usually the tail end 
because my school gets out later than hers does.”  Rob’s parents, on the other hand, were present 
only for games. 
 Parents’ perceived confidence in the participants’ coaches’ ability to respond 
appropriately to a diabetic emergency appeared to be a major factor in whether or not parents felt 
they needed to be present.  As noted above, Ryan’s father was always one of his coaches, and his 
mother was present for games.  Rose’s mother noted that “It’s men coaches…they’re doing the 
school’s team…they’re not really comfortable.  You can tell when somebody’s comfortable 
watching your child and you can tell when somebody’s not.  The coaches really aren’t 
comfortable if something should happen.”  Marie’s mother took an active role in preparing the 
softball coaches:  
Well, the one…she has a male and a female coach…the female coach was more the one 
that kinda wanted to be…the more motherly of the two…so, we just went over it after 
practice one day.  I showed her how Marie’s glucose meter works and showed her how to 
prick her finger if she ever had to do it.  We went over the glucagon…she went to the 
school nurse at the middle school as well and went over some stuff with her too.  
 
Rob’s mother has also been active in preparing his soccer coaches, stating: 
 
I would just go and…from the very beginning…make sure I talked to the coaches.  And 
make sure that they knew…just give them a basic overview…he’s always been very good 
about managing his pump, so I just tell them, “He’ll check his blood sugar before, if it’s 
too low, he won’t be able to play; if it’s too high he won’t be able to play.  You should be 
checking it during the game; he’ll check it after the game.  He can play just fine.  It 
doesn’t affect him in any way, shape, or form…but, just so you’re aware.” 
 
She reported that her husband was more involved with rugby, but that she demanded, “You have 
to let the coach know!  These people have to know!”  She further commented that she felt more  
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comfortable knowing that the team had an athletic trainer who was “knowledgeable about 
everything.”  
Most participants also referenced their friends/teammates and their parents.  Rose 
referred to one of her close friends and teammates as “Momma Bear,” explaining that she is very 
aware of her condition and frequently checks on her.  Her mother stated, “I do let her go spend 
the night with friends…those moms will get up at two in the morning…and take an active role.”  
Marie explained that, “We’ve all played together…they’ll like, if I look like I feel bad, they’ll 
ask me if everything is ok…they watch out for me and everything.”  Rob’s mother expressed, 
“His friends are great, and they all know about him being diabetic…they know all about highs 
and lows…but they’re still 15.” 
A final concern reflected within this theme is travel.  Marie’s mother explained that for 
school away games, “They have to ride the bus to away games to be eligible to play…she takes 
her insulin pen in case there is a malfunction…before we get there.”  For Rose, travel without 
her parents was rare, as her mother indicated discussing a mission trip, “I would have gone on 
that.  Her brother is her youth minister, and her sister-in-law stayed in the same room…they 
check her every three hours…she wouldn’t have done if they hadn’t gone.”  Rob’s mother 
expressed concern about allowing him to travel without his parents to rugby games and practices, 
stating, “Every once in a while he’ll [Rob’s stepfather] go, but usually he just gets a ride…which 
just gives me a heart attack every night…and I just go crazy the whole time.”  In addition, she 
explained that she did not feel comfortable allowing him to travel with the rugby team:  
He’s trying to convince me to let him travel with the guys, but no, that’s not 
happening…We would go with him.  It’s a combination of him being 15…with a bunch 
of 18 to 21 year old guys…that’s probably 95% of it… but I just don’t think he’s quite at 
an age where I can just let him…school trips…I feel different  
there because there’s teachers and adult chaperones, you know? 
In summary, four themes emerged from analysis of interview transcripts that describe 
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these adolescent athletes’ experiences with using CSII.  These themes, along with corresponding 
subthemes, were protecting the pump and infusion site; dealing with the highs and lows; 
maximizing participation and performance; and keeping watch.  A discussion of these results, as 
well as implications for practice, follows in Chapter Five.
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Chapter Five: Discussion 
This study sought to explore and describe the experiences of adolescent athletes with 
T1DM who use CSII as their primary insulin delivery method, in terms of athletic participation 
and performance.  A thorough review of the literature, which demonstrated a paucity of research 
describing CSII use in this population, reflected that previous research has focused on transition 
from MDIs to CSII, advantages and disadvantages of CSII, and impact on quality of life (Alsaleh 
et al., 2012).  Health care professionals can utilize the documented experiences of adolescent 
athletes using CSII from this study to anticipate the needs and concerns of this population when 
developing management strategies.  Acknowledging that these adolescents face unique 
challenges compared to their non-athletic peers is relevant to advanced nursing practice and to 
others involved in athletic participation.   
While the chronic illness trajectory model was the initial theoretical framework for this 
study, analysis of the transcripts revealed that a different framework, the shifting perspectives 
model of chronic illness, was more appropriate for this population.  Four core themes emerged to 
describe the athletes’ experiences, along with several subthemes: protecting the pump and 
infusion site; dealing with the highs and lows; maximizing participation and performance; and 
keeping watch.  This chapter examines the findings of the study in relation to established 
research, the limitations of the study, implications for practice, and recommendations for future 
research.   
Shifting Perspectives Model of Chronic Illness 
The initial theoretical framework, the chronic illness trajectory model, was chosen with 
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the focus of determining how health care professionals can collaborate with individuals to shape 
the trajectory of T1DM.  However, analysis of the transcripts revealed that, while this framework  
is appropriate for understanding and shaping the course of chronic illness itself, it does not 
accurately reflect these athletes’ experiences.  Rather, the shifting perspectives model of chronic 
illness may serve as a more fitting lens to view the effect of CSII on athletic participation and 
performance.   
The shifting perspectives model of chronic illness, which developed from a meta-analysis 
of 292 qualitative studies, explains living with a chronic illness as “an on-going, continually 
shifting process” (Paterson, 2001, p. 23).  The model suggests that individuals living with a 
chronic illness view their lives according to the amount of wellness or illness in the foreground 
of their current experience.  The term perspective refers to the individual’s values, beliefs, 
expectations, and feelings about the experience.  This, in turn, determines their response to the 
illness, themselves, caregivers, and situations affected by the illness (Paterson, 2001).  In this 
instance, the situation in question is athletic participation.   
Paterson (2001) stated that individuals with illness in the foreground, characterized by a 
focus on the associated sickness, suffering, and loss, tend to be preoccupied with the illness and 
may have difficulty attending to other tasks or needs.  In essence, the individual defines their 
identity in terms of the illness.  Diagnosis or onset of new complications or symptoms is often a 
trigger for illness to shift to the foreground.  By focusing on the illness, the individual can learn 
about the illness or complication and come to terms with it (Paterson, 2001).  On the other hand, 
individuals with wellness in the foreground recognize that their illness does not define their 
identity.  Paterson (2001) pointed out that, while these individuals experience illness-related 
impairments, they often describe their health as good or excellent, demonstrating that they have 
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altered their view of what is possible and normal.  Individuals gain this perspective through 
learning about the disease, creating supportive surroundings, developing personal skills, and 
understanding their body’s responses (Paterson, 2001).  An individual may shift perspectives 
multiple times over the course of an illness.   
 Paterson (2001) explained that there are several paradoxes involved in this model, the 
most significant being that illness requires attention in order for the individual to be able to 
ignore it.  Essentially, the individual must acknowledge the presence of disease while 
simultaneously “rejecting the limitations and significance of it” (Paterson, 2001, p. 25).  
However, a desire to maintain wellness in the foreground may actually compel an individual to 
ignore disease-related changes, and can eventually lead to disease progression (Paterson, 2001).  
Further, an individual with wellness in the foreground may have to shift perspectives in order to 
receive health care services as most interventions focus on mitigating illness, not promoting 
wellness.  Finally, in order to manage the illness and keep wellness in the foreground, individuals 
must seek health care from practitioners who may view them as helpless, thus emphasizing 
illness (Paterson, 2001).   
 In light of analysis of the themes that emerged, the shifting perspectives model seems to 
fit these athletes’ experiences well.  The general tone of the interviews reflected that, especially 
during athletic participation, wellness is predominately in the foreground.  Shifting occurs when 
diabetes demands attention, such as when complications lead to interruptions in participation or 
when the athlete must check blood glucose or give an insulin bolus in anticipation of or during 
participation.  
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Discussion of the Findings  
Protecting the Pump and Infusion Site 
Choosing infusion sites that did not interfere with participation and protecting the site or 
pump during activity were significant concerns for all of the athletes interviewed, but each 
demonstrated that they have developed tactics to prevent losing sites during participation.  
Effectively protecting the insulin pump and preventing the loss of infusion sites is crucial to 
families, given that insulin pumps cost approximately $6000, with an additional $200 per month 
for supplies (ADA, n.d.; Soraya et al., 2002).  In addition, losing the site during participation, or 
worse, damaging the pump itself, could result in acute complications that preclude participation 
and hinder performance.  These descriptions help fill a gap in research regarding managing the 
pump during activity described by Low et al. (2005) as “an unresolved issue” (p. 28).    
Dealing with the Highs and Lows 
Preventing hyperglycemia and hypoglycemia prior to and during athletic participation 
requires advance planning and education.  In their book about CSII, Walsh and Roberts (2012) 
stressed that athletes must take into account intensity and duration of exercise and provided 
several guidelines for maintaining adequate blood glucose levels during activity.  They 
recommended that consuming extra carbohydrates is ideal for balancing exercise, specifically 
suggesting converting exercise intensity and duration into “ExCarbs” to estimate the 
carbohydrate need per hour of exercise.  For example, a 100lb athlete uses approximately 45 
grams of carbohydrate per hour.  The athlete can then use that calculation to eat more 
carbohydrate, take less insulin, lower a high glucose, or a combination (Walsh & Roberts, 2012).  
The athletes and their parents demonstrated understanding of how to approach this problem and 
that they are taking appropriate steps, such as checking glucose, reducing basal rates, and eating 
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before participation (ADA, 2012b; Shugart et al., 2010; Silverstein et al., 2005).  In addition, 
Walsh and Roberts (2012) discussed that athletes must also be aware of the impact of counter-
regulatory hormones involved in intense or competitive exercise.  At least two participants 
mentioned the role of “adrenaline” when discussing managing post-exercise hyperglycemia.  
However, the participants verbalized that they employ several methods when making decisions 
about pump management.  Their use of alternative means such as “guesstimating,” “fine-tuning,” 
“trial and error,” and experience-based adjustments suggests that this population lacks definitive 
means of determining appropriate correction doses prior, during, or after activity.   
 Another major issue for these athletes is the ongoing problem of early morning 
hypoglycemia.  This concern, of course, is congruent with literature regarding post-exercise, late-
onset hypoglycemia as discussed in Chapter Two (Shugart et al., 2010; Silverstein et al., 2005).  
Participant experiences reveal that, despite appropriate measures as recommended by their 
physicians and available literature, these athletes have not been able to find effective means of 
preventing this distressing phenomenon.  When asked about eating immediately after activity, 
most participants stated that they only ate if they were hungry.  Walsh and Roberts (2012) 
suggested that consuming carbohydrate and protein within the first 20 to 30 minutes after long or 
strenuous exercise allows rapid muscle glycogen restoration and muscle repair and can reduce 
the risk for delayed or nocturnal hypoglycemia.  It is possible that, especially with the intensity 
and competitive nature of the sports these athletes described, an immediate post-exercise snack, 
such as chocolate milk, would be beneficial.  However, the guidelines set forth in previous 
literature were designed for adults, and most adult athletes are eventually able to predict when 
they will experience hypoglycemia (Colberg, 2009; Doyle et al., 2005; Hornsby & Chetlin, 
2005).  As one participant’s mother pointed out, this phenomenon could also be unique to the 
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adolescent population related to physical development and hormonal activity (Walsh & Roberts, 
2012).  Participant concerns about late-onset hypoglycemia suggest bolus and basal adjustments 
may not always be effective.  Follow-up with health care providers needs to focus on evaluation 
of the effectiveness of postexercise hypoglycemia prevention.  
Maximizing Performance and Participation 
 Being different or drawing negative attention was described as a challenge for these 
athletes.  One participant explained that she was reluctant to give herself time to recover after 
interrupting a tennis match.  While this is representative of normal adolescent behavior, this type 
of behavior could bring about more severe complications in an adolescent who opts to continue 
competing despite experiencing symptoms of hyperglycemia or hypoglycemia (Comeaux & 
Jaser, 2010).  
Keeping Watch 
Discussions with the adolescent athletes and their parents revealed that they shared 
responsibility for managing the insulin pump at varying levels.  Consistent with 
recommendations in the literature (Comeaux & Jaser, 2010; Silverstein et al., 2005), the division 
of responsibility did not seem directly influenced by chronologic age.  Rather, parents appeared 
to determine this division based on their perceptions of maturity.  Self-management guidelines 
provided by Walsh and Roberts (2012) suggest that, by 12 years of age, a child should be able to 
reliably count carbohydrates, test blood sugar, calculate and give a bolus, and insert an infusion 
set.  Low et al. (2005) reported that often parents note that adolescents are more comfortable 
with the insulin pump’s technology than they are.  However, health care professionals should be 
aware that physical and motor skills do not equate to an adolescent having the emotional 
maturity or problem-solving skills needed to manage T1DM or CSII effectively (Keough et al., 
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2011; Silverstein et al., 2005).  As mentioned previously, studies have demonstrated a positive 
correlation between continued parental involvement and glycemic control (Comeaux & Jaser, 
2010; (Keough et al., 2011; Silverstein et al., 2005).  Optimal transfer of responsibility involves a 
gradual shift from the parents to the adolescent, and may vary depending on the adolescent’s 
need for support at a given time.  Further, as circumstances influence the adolescent’s 
responsibility, parents and adolescents, along with the healthcare team, must engage in 
continuous negotiation and clarification of responsibility (Olinder et al., 2010).   
These parents demonstrated being very proactive in seeking out additional information to 
assist them in managing the athletes’ diabetes.  In addition, they cited several areas where they 
felt there is a need for more education, including carb counting and food choices, using advanced 
pump settings, and a training specific to managing diabetes when playing sports.  The need for 
continued frequent contact, beyond initial pump training, is congruent with Shalitin and Phillip’s 
(2008) review.  However, the authors did not specifically identify subject areas for advanced 
pump education.  Desires expressed for additional education suggest that specially tailored 
education for athletes would be beneficial.  In addition, reports of initial education specific to 
CSII varied from 10 to 24 hours, despite all of the participants initiating therapy at the same 
pediatric endocrinology practice.    
 Limitations and Recommendations 
 While qualitative description provides a rich description of the participants’ experiences, 
the method is not without drawbacks.  Fortunately, limitations also present opportunities for 
future research.  The sample demographics could potentially provide for bias.  Though this was 
designed to be a pilot study, with a relatively small scope, there was a lack of diversity that could 
contribute to bias, as all participants were Caucasian, English-speaking, of mid- to upper 
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socioeconomic status, and were early adolescents between 13 and 15 years of age.  Additionally, 
adolescents with elevated HgbA1Cs were excluded with the intent of interviewing only those 
athletes who have been successfully managing their diabetes.  Further exploration with a more 
diverse sample or a sample including adolescent athletes who have not been able to maintain 
desirable HgbA1Cs would likely elucidate different concerns.  Furthermore, since older 
adolescents are likely to be more independent, including 16- to 18-year-olds would likely 
provide additional information about management strategies.    
 Participants were recruited from and continue to seek care from a clinic that has a strong 
reputation for excellence in patient care.  As such, responses related to adequacy of education or 
support may have been constrained.  For example, more than one parent preceded her comments 
on education needs with a disclaimer of how wonderful her doctors and educators have been.  
Responses of participants from varied institutions could yield different results.   
 Answers to the interview questions could have been affected by the chosen methodology.  
The researcher’s inexperience with interviewing, especially adolescents, and the lack of rapport 
established could have influenced the amount or type of information provided.  The researcher’s 
comfort and experience with the adolescent population was likely an advantage to counteract her 
inexperience as an interviewer, but bears mentioning nonetheless.  In addition, responses may 
have been influenced by how the participants wanted to be seen by the researcher.  Further, it is 
important to note that the researcher set out to interview solely the adolescent athletes.  After the 
first interview, it became apparent that, at this age, parents are still so involved in diabetes 
management that their responses were essential.  This necessitated an amended IRB review.  All 
participants were interviewed with their mothers present; future exploration could include 
fathers’ perspectives as well.  Further research by a researcher with more experience in  
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interviewing adolescents is warranted.   
 Furthermore, with the chosen methodology, data collection was limited to one face-to-
face interview with the adolescent athlete and their parent.  Additional sources of data, including 
observation, focus group interviews, or additional interviews with peers or coaches could yield a 
richer description.  Member checking with participants could have further supported 
trustworthiness.   
 Episodes of early morning or late-onset hypoglycemia continue to be a significant 
problem.  As mentioned, evidence of this phenomenon, despite appropriate actions by the 
participants indicates that this may be unique to the adolescent population.  Further research with 
adolescent athletes is necessary to determine how aspects of physical development in this 
population may influence this phenomenon.  Additional research, based on measured outcomes, 
is also needed to determine what advanced education this population requires.   
Implications 
 The experiences of the adolescent athletes in this study allow for multiple suggestions to 
the diabetes management team, as well as to coaches or athletic trainers.  Understanding the 
unique needs of adolescent athletes with T1DM is essential for nurses, especially those in 
primary care and school settings.  Nurses have a pivotal role as advocate and educator and must 
be prepared to address questions adolescents and their parents may have regarding athletic 
participation and performance.  School nurses, particularly, must be equipped with appropriate 
strategies and should collaborate with coaches and trainers to ensure that athletes practice and 
compete safely in physically demanding situations.  Coaches and athletic trainers should be 
trained in the fundamentals of recognizing and managing hypoglycemia and hyperglycemia, 
including glucagon administration.  
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 These athletes and their parents demonstrated great respect for the physicians and 
advanced practice nurses, including certified diabetes educators, involved in their T1DM 
management.  They value and utilize the guidance and knowledge the team has provided.  
However, participants explained that they have been compelled to do a great deal of independent 
research and use “trial and error” approaches when attempting to maximize athletic participation.  
For example, one participant’s innovation of injecting insulin from her pen when her pod is 
running low indicates that, when patients are seen in clinic, health care professionals need to 
ascertain whether bolus activity has been limited to the pump or if other sources have been used.  
Health care providers and educators must be aware of these decision-making approaches and 
must inquire about these tactics to determine the best strategies for each athlete.  Additionally, 
with the aim of eliminating the need for these alternative approaches, it may be beneficial for 
these athletes to wear a CGM when participating in sports, especially when starting a new sport 
or season.  The athlete could then download and review results with a provider to determine 
basal and bolus settings that are more appropriate.  Further, clinic follow-up for adolescent 
athletes needs to focus on the effectiveness of methods to prevent postexercise hypoglycemia.  
Providers must also keep psychosocial factors in mind when creating management strategies.   
The varied descriptions of education received regarding the pump, as well as the 
suggestions for additional education indicate that current education approaches may not be 
sufficient for this population.  Members of the multidisciplinary team should be aware of these 
factors and strive to understand the unique needs of adolescent athletes using CSII.  A one-size-
fits-all approach to diabetes and CSII education is not adequate for this population.  Educators 
must take the time to carefully assess individual needs and provide advanced education when 
necessary.  Advanced education should entail use of advanced CSII functions, such as temporary 
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basal rates and reduced correction doses, as well as information on nutrition and hydration needs 
for athletes.  Consultation with an exercise physiologist familiar with diabetic athletes may also 
be valuable.   
Health care professionals should be aware of print or digital resources for athletes with 
diabetes, such as the Diabetic Athlete’s Handbook (Colberg, 2009) and Pumping Insulin (Walsh 
& Roberts, 2012).  There are also several internet resources available for children or athletes 
with T1DM.  Runsweet (http://www.runsweet.com), a website based in the United Kingdom, 
provides multiple resources for athletes, including children, including detailed management 
descriptions for various sports.  The Children with Diabetes, Inc. website 
(http://www.childrenwithdiabetes.org) features a host of resources including a “Sports Corner” 
which provides information for athletes with diabetes, as well as access to recent related studies 
and various support networks and blogs.  Parents and adolescents should be encouraged to use 
community resources, such as their local JDRF chapter or diabetes support groups.  In addition, 
the influence of social media on the adolescent population should not be overlooked.  Blogs, 
discussion groups, and other social networking activities could prove beneficial for these athletes 
and their parents.  Further, telehealth and smartphone applications could allow consultation or 
monitoring for those without immediate access to pediatric endocrinology services.   
This study was the first step in understanding the experiences and needs of adolescent 
athletes using CSII.  Clearly more research will be necessary to fully understand and address the 
continued difficulties these athletes face when trying to maximize participation and performance 
while maintaining tight glycemic control.  Further exploration will serve to strengthen these 
findings and educate health care professionals in addressing this population’s unique needs when 
developing and implementing management strategies.    
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Appendix A: Consent to Participate 
Approved by the Nemours IRB. Valid from: 11/8/2012 through 08/06/2013 IRB #: 355010 
Abbreviated Study Title: Adolescent athletes with Type 1 Diabetes 
 
NEMOURS  
JACKSONVILLE, FLORIDA 
PARENTAL PERMISSION FOR PARTICIPATION IN A RESEARCH STUDY 
 
You have been asked to permit your child to be in a research study. This form explains the research, your 
child’s rights as a research participant, and any responsibilities that you may have as a result of your 
child’s participation.  You should understand the research study before you agree to permit your child to 
be in it. Read this permission form carefully. You may also talk with your family or friends about it.  
A research team member will answer any questions you have before you make a decision.  
 
1. WHAT IS THE TITLE OF THE STUDY? 
Adolescent Athletes with Type 1 Diabetes: Experiences with Continuous Subcutaneous Insulin Infusion 
 
2. WHO IS IN CHARGE OF THE STUDY AT NEMOURS? 
If you have a question, complaint, or problem related to the study, you can call the investigator anytime at 
the numbers listed below.  
Doreen Radjenovic, PhD, ARNP                                 Regina S. Tow, RN, BSN, CPN                                                                       
Phone: 904-697-3674               Phone: 954-673-6224 
Email: dradjeno@unf.edu                                            Email: n00808996@ospreys.unf.edu 
 
3. WHO SHOULD RESEARCH PARTICIPANTS CONTACT ABOUT THEIR RIGHTS? 
If you have questions about your child’s rights as a research subject, what to do if your child is injured, if 
you would like to offer input or obtain information, or if you cannot reach the investigator or want to talk to 
someone else who is not involved with this research, you may contact the persons listed below. 
Tim Wysocki, Ph.D., Chairperson, Nemours-Florida Institutional Review Board at (904)-697-3415.  
Paul Garfinkel, MSH., Director, Nemours Office for Human Subjects Protection, at (904) 697-4023.  
(Nemours Long Distance Operator) (800) SOS-KIDS (800-767-5437)  
Website: http://teamshare/patient/nohsp/default.aspx.  Email address: NOHSP@nemours.org. 
 
4. WHAT IS THE PURPOSE OF THE STUDY? 
The purpose of this study is to explore and describe the experiences of teen athletes with type 1 diabetes 
who use insulin pumps. Findings may be used to understand the issues and concerns of  teen athletes.  
This will prepare healthcare providers to address these  issues when planning diabetes care.  
 
5. WHO CAN BE IN THE STUDY? 
To participate in the study individuals must meet the following criteria: between 13 and 17  years of age, 
diagnosed with type 1 diabetes for at least six months, able to speak English well, using an insulin pump 
as their primary insulin delivery method, currently in good diabetes control (HgbA1C ≤ 7.5%), must have 
participated in organized sports activities at least three days a week during the spring or summer of 2012, 
and must not be currently participating in another study at NCC-J.  
 
6. HOW LONG WILL PARTICIPATION IN THE STUDY LAST? 
Participation is limited to one interview lasting approximately 60 minutes.  
 
7. WHAT ARE THE RESEARCH PROCEDURES? 
A face-to-face interview will focus on athletic participation and performance.  Interviews will be conducted 
in a private area of the clinic.  Your child will be asked to provide basic  information ,such as age, date of 
diagnosis, and details about their sport. There will be no change in the usual medical care of participants. 
Interviews will be audio-recorded and transcribed, and additional notes may be taken during the interview.  
If you choose to be present for the interview, any responses you give may also be considered. All 
recorded material will be destroyed at the end of the study. 
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8. WHAT ARE POSSIBLE RISKS OF BEING IN THIS STUDY? 
The risks involved in this study are the same as the risks your child would ordinarily encounter in daily life 
or during a routine physical examination. This research is observational which means that there is no 
change to any treatment that your child may be receiving.  The possible risks are described below. 
 
You or your child may feel uncomfortable talking about some negative issues about wearing a pump and 
athletics during the interview.  
 
9. WHAT ARE POSSIBLE BENEFITS OF BEING IN THIS STUDY? 
There are no direct benefits to participants in this study. However, others may benefit from the information 
we learn from the results of this study. 
 
10. IS BEING IN THE STUDY VOLUNTARY? 
Being in this study is totally voluntary. Anyone who takes part in the study can stop being in it at any time. 
There will be no change to your child’s usual medical care if you or your child decide not to be in the 
study or decide to stop being in the study. No one will be angry with you or your child, or treat your child 
any differently than before your child was asked to be in the study.  
 
You may ask the researcher to destroy your child’s information or samples.  Your request must be in 
writing.  The researcher will tell you if this is possible.   
 
11. WHAT ARE THE COSTS OF BEING IN THIS STUDY? 
You are responsible only for travel to and from the clinic and the time involved in completing the interview.  
 
12. WILL PEOPLE BE PAID FOR BEING IN THIS STUDY 
Your child will receive a $10 Target gift card as compensation for taking part in the study. The gift card 
will be presented at the interview 
 
No arrangement exists that would allow participants to share in any profit generated from this study or 
future research. 
 
13. WHAT INFORMATION ABOUT MY CHILD WILL BE USED OR DISCLOSED?   
Identifiable health information about your child will be used by Nemours researchers and may be given to 
people outside of Nemours for this research. This is done to conduct the research study, to monitor the 
safety of research participants and for auditing. Federal law requires us to tell you about, and get your 
approval for research use and disclosure of health information that includes “identifiers” that can connect 
the health information to your child. (Names, initials, date of birth, addresses, phone numbers, and social 
security numbers are examples of identifiers.) This Identifiable health information is called Protected 
Health Information (PHI). 
 
Use of Health Information by Nemours Staff 
The health information that will be used within Nemours includes all data collected for this study, as 
described in Section called "What Are the Research Procedures?". 
 
Your and your child’s identity will be protected as much as possible.  Nemours protects your and your 
child’s health information by storing records in files or computers that can only be used by authorized 
Nemours staff. 
 
Your child’s interview will be assigned a numeric code to protect your identities. .  
 
The people within Nemours that may use this health information include: 
 The investigators listed on the first page of this permission form and their staff,  
 The Nemours Institutional Review Board (IRB) (The IRB is a group of people that reviews 
research activities.  The IRB is responsible for the safety and rights of research participants), and; 
 Nemours internal audit staff. 
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Disclosure of Health Information to Others  
 
Identifiable health information will be given (disclosed) to the following individuals or groups:  
 Regina Tow, RN, BSN, CPN (graduate student) 
 Doreen Radjenovic, PhD, ARNP (University of North Florida faculty/thesis committee chair) 
 
The PHI that will be given (disclosed) to people or groups outside of Nemours for research purposes  
Type of Identifiable Health Information: Disclosed  
 
Demographics (information about age, diabetes diagnosis, pump initiation 
date, etc.) 
 
  
 
Limits on Protection of Privacy and Confidentiality 
Only health care organizations have to follow laws and rules about protecting the privacy of health 
information. If health information containing peoples' identities is given to other kinds of companies or 
organizations, they are not required by law to safeguard the privacy and confidentiality of that information. 
Nemours expects these companies and organization to protect the privacy and confidentiality of research 
participants, but it is not possible for Nemours researchers to assure that this happens. 
 
Government agencies that may look at records for this research study, including the above health 
information, include:  
 The U.S. Food and Drug Administration  
 The U.S. Department of Health and Human Services  
 Other agencies of State and local government as required by law 
 Governmental agencies in other countries  
 
The research results may be presented at scientific meetings or in print.  Participants' identities will not be 
disclosed in those presentations. 
 
14. SIGNATURES: 
I am making a decision whether or not to permit my child to participate in this study. I understand that my 
child may also have to agree to participate in the study before he/she will be allowed to be in this study.  I 
have read this form, or have had it read to me in a language that I understand. I have been given enough 
time to make this decision. I have asked questions and received answers about things I did not 
understand.  I willingly give permission for my child to participate in this study.  By signing this form, I am 
not giving up any rights to which I am entitled under law. 
 
I understand that: 
 I can withdraw permission for participation in this study and for the use and/or disclosure of PHI by 
contacting the person in charge of the study listed on the first page of this form.   
 The use and/or disclosure of my child’s PHI will stop after Nemours receives the withdrawal notice.  
Information that is used or disclosed before the withdrawal may still be used. 
 Unless I withdraw permission, the use and/or disclosure of PHI described in this form will expire when 
the research study is complete and analysis and publication have ended. 
 My child’s PHI may be disclosed again by the person or organization (other than Nemours) that 
receives it.  If this happens, Federal or state law may not protect the information. 
 I have the right to refuse to sign this permission form. 
 If I refuse to sign this permission form, my child will not be allowed to be in this research study. 
 I have the right to ask Nemours to tell me who has received my child’s protected health information.  
 I have the right to revoke my permission for the use and disclosure of my child’s health information at 
any time, which would end his/her participation in this study. 
 I will receive a signed and dated copy of this form.  
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My signature indicates that: 
 As his or her parent or guardian, I give my permission for the minor child named below to 
participate in the research study described in this Parental Permission Form. 
 
 I give the researchers and Nemours permission to use and/or disclose my child’s individually 
identifiable health information for this research study as described in Section 19. 
 
 
 
Name of Participant (Print)  Participant Date of Birth:   
     
     
Signature of   Printed Name of   Date 
Parent / Guardian  Parent /  Guardian   
     
 
Check Relation to Participant:    __ Parent   __ Guardian: (Guardians must have documented authority to 
give permission for participation in a research study according to the laws of the State in which the 
treatment occurs.)  
 
 
I the undersigned, certify that to the best of my knowledge the parent/legal representative signing this 
permission had the study fully and carefully explained and that he/she understands the nature, risks and 
benefits of participation in this research study. 
 
Name of Person Obtaining 
permission (Investigator or Designee) 
 Signature of Person Obtaining 
permission 
 Date 
 
Copy of the signed form was provided to Parent/ Guardian on [Date] ___________ 
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Approved by the Nemours IRB. Valid from: 08/07/2012 through 08/06/2013 IRB #: 355010 
Abbreviated Study Title: Adolescent athletes with Type 1 Diabetes 
 
ADOLESCENT ASSENT FORM FOR YOUTH AGES 12-17 
 
Your parent has given permission for you to be in a project called a research study. But first, we want to tell you all about it so you 
can decide if you want to be in it. If you don’t understand, please ask questions. You can choose to be in the study, not be in the 
study or take more time to decide. 
 
What is the name of the study? 
Adolescent Athletes with Type 1 Diabetes: Experiences with Continuous Subcutaneous Insulin Infusion  
 
Who is in charge of the study? 
Dr. Doreen Radjenovic (clinic Nurse Practitioner) 
 
What is the study about? 
We would like to find out what it is like to play sports and wear an insulin pump o that doctors and nurses can learn more and help 
others who plan to wear a pump during sports. 
 
Why are you asking me to be in this study? 
You are being asked to be in the study because you use an insulin pump and have recently participated in organized sports. 
 
What will happen to me in the study? 
You will take part in a face-to-face recorded interview that will last no more than 60 minutes. There will be no physical pain or 
discomfort involved. Your recorded interview will be kept private and confidential using special code, and only Dr. Doreen 
Radjenovic and Ms. Regina Tow will see your responses. At the end of the study, all recorded data will be destroyed.  
By participating in this study, you will be helping doctors and nurses who care for children with diabetes better understand the 
concerns of  teens wearing  insulin pumps and will help them to develop better plans to manage athletes with diabetes.   
 
Will I be paid to be in this study? 
You will be paid for being in this study. You will receive a $10 Target gift card at  your interview.   
 
Do I have to be in the study?   
You don’t have to do the study if you don’t want to. If you are in the study, you can stop being in it at any time. Nobody will be upset 
with you if you don’t want to be in the study or if you want to stop being in the study. The doctors and nurses will take care of you as 
they have in the past. If you have any questions or don’t like what is happening, please tell the doctor or nurse. 
 
You have had the study explained to you. You have been given a chance to ask questions. By writing your name below, you are 
saying that you want to be in the study. 
 
 
Adolescent’s Signature  Date   
     
     
Name of Person Obtaining Assent  Signature of Person Obtaining Assent  Date 
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Appendix B: Demographic Information  
Participant Demographic Questionnaire 
Today’s date: __________________ 
Your date of birth: ______________ 
Month/year you were diagnosed with diabetes: _____________ 
Month/year you started using an insulin pump: _____________ 
Brand of your insulin pump: (circle one) 
 Animas    Medtronic    Minimed   Omnipod   Other: ________ 
Your last hemoglobin A1C:   _____________     ______________ 
                                                     Date                          Result 
Number of hours of diabetes education specifically related to using an insulin pump: ___ 
Grade you last completed in school: (circle one) 
   7        8        9        10       11        12   
Type of sport(s) you played in spring/summer 2012: _______________ 
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Demographic Results 
Participant 
Number/Pseudonym 
01 
Ryan 
02 
Rose 
03 
Marie 
04 
Rob 
Age (years) 13 13 13 15 
Sex 
 
M F F M 
Most recent HbgA1C (%) 6.9 7.2 6.7 7.2 
Ethnic background/race Caucasian Caucasian Caucasian Caucasian 
Age of T1DM diagnosis 
(years) 
 
6 11 6 9 
CSII duration (years) 5 1 (18 mos) 6 4 
CSII device in use Minimed OmniPod Animas Animas 
Last grade completed in school 
 
7 6 7 9 
Sport played in 2012 Soccer 
Football 
Tennis 
Volleyball 
Softball 
Volleyball 
Soccer 
Rugby 
Contact sport (yes/no) Yes No No Yes 
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Appendix C: Interview Questions  
                                                                                    Gender: __________________ 
       Race: ____________________ 
                                                                                    Time Started: ______________ 
Date : _____________                                               Time Ended: _______________ 
 
1. Tell me about the sport you played last season.  
 Prompts:  
  -How many days of the week/hours per day did you participate? 
  -Were your parent(s) present at practices/games? 
  -How many participants/coaches? 
2. Tell me about the sport you played last season and wearing your insulin pump.  
 Prompts:   
-What was the biggest challenge in wearing a pump during practice or play? 
 
-Was this your first attempt or have you played with a pump before? 
  -Did you need to disconnect your pump to participate? How long?  
  -How often did you test your blood glucose before/during/after activity? 
  -How did you manage protecting your insulin and the pump during     
                         practice or play? 
 
-How did you feel about your teammates’ or coaches’ response to the pump? 
 
-How did you manage to prevent hypoglycemia or hyperglycemia during 
practice/play? 
 
3. How do you feel using the pump impacts your performance? 
 Prompts:  
 76 
-What changes, if any, have you had to make when using the pump during 
athletics? 
 -basal settings? 
 -infusion sites? 
 -pre-activity boluses? 
 -eating before or after participation? 
 
-What are the advantages to wearing a pump and participating in athletics? Any 
disadvantages? 
 
-How does your practice or play impact the rest of the day? Rest of the week? 
 
-What adjustments in CSII or eating do you need to make after practice or play? 
 
-What adjustments is CSII do you need to make on days with no practice or play? 
  
Is there anything else you would like to talk about regarding your pump? 
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Appendix D: University of North Florida IRB Approval 
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Appendix E: Nemours IRB Approval
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